Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Vorinostat (SAHA, MK0683) Chemical Structure

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 220 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 104 Publications

20 Customer Reviews

  • Activity of vorinostat in Jurkat and Peer T-ALL cell lines in an MTT cell viability assay. Cells were treated with increasing drug concentrations for 72 h. The data are plotted as the mean % of DMSO-treated control cells against the corresponding drug concentration. The error bars are the standard error. For each drug and cell line, 3-4 independent experiments were performed with 6 replicates at each drug concentration.

    Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Differential effects of HDAC inhibitors on histone and tubulin acetylation. Immunofluorescence analysis of histone H3 (K9ac/K14ac) and tubulin acetylation in HeLa cells treated for 4 h with vehicle, SAHA (10 μM), tacedinaline (50 μM), PCI-24781 (20 μM. (a) Mapping of histone acetylation in K562 cells treated with HDAC inhibitors by LC-MS/MS. Cells were treated with TSA (10 μM), SAHA (5 μM), PCI-24781 (2 μM), tacedinaline (50 μM) for 6 h. Histones were extracted from cells and acetylated peptides were quantified after isobaric tagging.

    Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Western blot analysis of histone H3 acetylation in the spleen of untreated and vorinostat-treated hNF-E2 tg mice (n = 4 of each genotype).

    J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA down-regulates c-FLIP expression and increases the sensitivity of CaP cells to undergo apoptosis in the presence of bicalutamide (A) Bar graph illustrating the sub-G0/G1 cell population in 22Rv1 (left panel) and LNCaP (right panel) cells in the absence and presence of 10μM bicalutamide, administered as a single agent or in ombination with increasing concentrations of the HDAC inhibitor, SAHA. (B) Immunoblots demonstrating the single agent activity of bicalutamide or SAHA, or effect upon their combined administration on the expression of c-FLIP and/or the processing of PARP. Equal protein loading was confirmed by GAPDH. (C) Bar graph illustrating the effect of bicalutamide and SAHA upon the induction of caspase-8 or caspase-3/7 activity in 22Rv1 cells (left panel) and LNCaP cells (right panel). (D) Immunoblots characterizing the impact of SAHA and/or bicalutamide upon the induction of PARP cleavage, in the absence or presence of the pan-caspase inhibitor, ZIETD. ZIETD was incubated with the cells for 12 h prior to the experiment. All data points shown in (A) and (C) represent the mean ± S.E.M. value, calculated from four independent experiments.

    Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Analyses of efficacy, potency and IC50 of HDAC inhibitors point toward HDACs 1–3 as relevant candidates for beta cell protection. Ranking and raw data on ITF drugs (Table 3) and commercial HDAC inhibitors (Table 4) underlying the heat maps of Fig. 1 (A and B). The HDAC inhibitor compounds were tested using a HDAC activity kit and recombinant proteins to determine IC50 values on each individual HDAC (right part of the table). Each drug was further tested using Real-Time Cell Analysis (RTCA) to score their maximal effective concentration (ECmax) as well as the corresponding rescue percentage of cytokine treated INS-1 cells. The drugs were ranked according to % rescue. * DMSO alone controls were included in each experiment, but not shown here. The results indicate that the highest concentrations of DMSO used here (1:1,000) were slightly potentiating the proliferation of the cells. The effects observed in this group of compounds were ascribed to the DMSO.?

    Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice. (a) CFP (+) mitochondria were longer and thicker in MONs from 12-month-old Thy-1 CFP mice (inset; scale bar = 2 μm). Oxygen–glucose deprivation (OGD) consistently reduced CFP pixel intensity in 12-month-old MONs despite longer and brighter CFP ( +) mitochondria (yellow arrows). (b) Blockade of AMPA/kain ate receptors with NBQX (30 μM), or pan-Histone deacetylase (HDAC) inhibition with SAHA (5 μM), effectively preserved CFP pixel intensity during OGD. The preservation of CFP (+) mitochondria correlates with protection of the CAP area during OGD and profound recovery.

    J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • D and E, Regression of IL-13Ra 2-negative pancreatic tumors treated with SAHA and/or IL-13-PE. Mice were treated daily with i.p. injection of SAHA (25 mg/kg) from day 4 after tumor implantation for two weeks followed by i.t. injection of IL-13-PE (100 μ g/kg) from day 5 for two weeks. F and G, Regression of IL-13Ra 2-posotive pancreatic tumors (HS766T and MIA-PaCa2) treated with SAHA and/or IL-13-PE. The schedule of treatment was similar as in panel D and E. Statistical significances are shown by *: P < 0.05,†: P < 0.001.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

    IL-13Rα2 expression is upregulated in pancreatic tumors but not in organs of mice after treatment with HDAC inhibi tor, SAHA. A, qRT-PCR of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. Tumors were harvested next day after IL-13-PE treatment and total RNA extracted. Data shown is ratio of human IL-13Rα2/β-actin expression and multiplied by 1000 for convenience. Bars , SD of triplicate determinations. B, qRT-PCR of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Tissues were harvested at the same time point as in panel A and total RNA extracted. Data shown is ratio of mouse IL-13Rα2/β-actin expression and multiplied by 100 for convenience. C, IHC of human IL-13Rα2 in implanted pancreatic tumors after SAHA and IL-13-PE treatment. D, IHC of mouse IL-13Rα2 in mice organs after SAHA and IL-13-PE treatment. Liver, brain, kidney, pancreas, lung and spleen were fixed for immunostaining of mouse IL-13Rα2 as visualized by Alexa555. Nucleus was counterstained by DAPI.

    J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Proliferation o f HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment. Proliferation measurements using the xCEL Ligence RTCA DP instrument (Roche) in cells treated with increasing doses of butyrate or SAHA, compared with control medium cells (0) (*P < 0.05). The mean ?SEM of three cell culture replicates is shown.

    Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA induces the down-regulation of cFLIP expression and promotes TRAIL-mediated activation of a mitochondrial-operated apoptotic pathway. a BT-474 cells were treated as indicated in Fig. 1 and the cells were then harvested to analyse caspase-8, Bid, caspase-9, caspase-3 and PARP expression, using GAPDH as the protein loading control. b BT-474 cells were treated with SAHA for 8 h at the doses indicated and subsequently, the cells were harvested and the apoptosis-related proteins were analysed in western blots as described in the "Materials and Methods". The results shown are representative of at least three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Treatment with SAHA sensitizes breast cancer cells to TRAILinduced apoptosis. BT-474 and MDA-MB-231 cells were incubated for 8 h with SAHA at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some of the cultures for an additional 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content as described in the "Materials and methods". The results show the mean and S.E.M. of three independent experiments

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    SAHA facilitates the Itch/AIP4-independent proteasomal degradation of cFLIP proteins in breast cancer cells. a BT-474 cells were treated with SAHA (5 μM) for 8 h in the presence or absence of the proteasome inhibitors MG132 or epoxomicin (at the doses indicated), and they were then harvested and the cFLIP content was analysed in western blots. b BT-474 cells were transfected with either the siRNA oligonucleotides targeting Itch/AIP4 or the non-targeting RNA oligonucleotide (scrambled) for 48 h as described in the "Materials and Methods". Subsequently, the cells were treated with SAHA (5 μM) for 8 h and then cFLIP and Itch/AIP4 expression was analysed in immunoblots

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • cFLIP down-regulation following SAHA treatment is responsible for the sensitization of breast cancer cells to TRAIL. a BT-474 cells were transfected with either different siRNAs directed against the cFLIP isoforms or the non-targeting RNA oligonucleotide (scrambled) as described in the "Materials and Methods". After 24 h, the cells were treated with TRAIL (500 ng/ml) for a further 15 h and apoptosis was then measured as the percentage of cells with subG1 DNA content. The results show the mean and S.E.M. of three independent experiments. To verify protein knockdown, cells were harvested 24 h after transfection and the cFLIP levels were assessed in immunoblots. b. BT-474 cells overexpressing Cflipl (pBABE-FLIPL) or control cells (pBABE) were treated with SAHA for 8 h at the doses indicated. After this time, TRAIL (500 ng/ml) was added to some cultures for 15 h. Apoptosis was measured as the percentage of cells with subG1 DNA content and the results show the mean and range of two independent experiments. Western blots show the cFLIP levels after SAHA treatment in pBABE and pBABE-FLIPL cells.

    Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Vorinostat inhibits the tumor growth. NOD ⁄ SCID-B2m-/-mice were injected s.c. with 1×106 MyLa2059 cells into both flanks. When the mice had developed established palpable tumors treatment was initiated (day 1). The mice received either vehicle (black line) or 60 mg ⁄ kg vorinostat (grey line) i.p. five days a week. In total, there were four mice in the group receiving vehicle and three mice in the group receiving vorinostat. The length and width of the tumors were measured continuously until the experiment was terminated on day 20 post treatment initiation. The tumor volume was calculated using the formula V = (a×b2)/2, where a defines the length (mm) and b the width (mm) of the tumor. The histogram shows the average tumor volume per flank ± SEM. * denotes a significant difference (P < 0.05) in the average tumor volume per flank between mice treated with vehicle and vorinostat at the given time-point both by using a one-tailed two samples test with Welch, scorrection and a Mann-Whitney U test.

     

     

    Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Western blot of whole cell extracts demonstrates SAHA and NaB treatment result in increased levels of acetylated histone H3 compared to vehicle controls. (b) Light micrographs of HDACi/vehicle treated cultures illustrate the paucity of neurospheres in HDACi-treated cultures. (c) Quantitative analysis confirms SAHA and NaB inhibit the formation of neurospheres (diameter ≥ 50 μm) and increase the prevalence of small cell clusters (≥ 4 cell, diameter < 50 μm). (d) Flow cytometry using LIVE/DEAD cell stain confirms SAHA and NaB are minimally toxic compared to vehicle controls (n = 3). Scale bar = 100 μm.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    (a) EdU flow cytometry of live cell-gated adult mouse NSCs demonstrates SAHA (**p < 0.01) and NaB (***p < 0.001) significantly inhibit DNA synthesis. (b) Analysis of DNA content by flow cytometry reveals significant accumulation of adult mouse NSCs in G1phase of the cell cycle following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (c) Correspondingly the proportion of cells in G2/M phase is significantly reduced following SAHA (*p < 0.05) and NaB (*p < 0.05) treatment. (d) Fluorescence micrographs of HDACi/vehicle treated adult NSCs pulse-labeled with EdU for flow cytometry. Scale bar = 50 μm. Statistical comparisons performed using one-way ANOVA with post hoc Newman-Keuls multiple comparison tests.

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • (a) Immunofluorescence labeling of NeuN, GFAP and Olig2 cell fate markers reveals reduced expression of GFAP (*p < 0.001) and Olig2 (*p < 0.05) in adult mouse NSCs treated with SAHA for 48 hours under proliferation culture conditions and then induced to differentiate for 14 days in culture (two-way ANOVA with Bonferroni post-tests). (b) Western blot of β-catenin protein in nuclear and cytoplasmic fractions of adult mouse NSCs treated with HDACi/vehicle control under proliferation culture conditions. Gapdh and lamin A/C blots are included as loading controls. (c) SAHA and NaB do not significantly alter nuclear/cytoplasmic levels of β-catenin in adult mouse NSCs. Histogram of β-catenin Western blot signal intensities normalized to loading controls (n = 4).

    BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Morphological changes and histone H3 phosphorylation of HB cells treated with a combination of VX-680 and SAHA. HUH6 and HepT1 were incubated with VX-680 (6 μM) and SAHA (0.5 μM). Nuclei diameter (a) and cell diameter (b) were determined 72 h later by DAPI staining and microscopy. Data represent mean±SD of the diameters from 20 cells in each experiment. (* Two-way ANOVA, Bonferroni test, p \0.05). c Western blot analysis on HUH6 and HepT1 cells were carried out with an anti-phospho-Histone H3 (Ser 10) antibody (p-H3) 24 h after incubation with VX-680 (10 μM), SAHA (0.2 μM) or a combination of both. Controls were left untreated. Western blot analysis showed a decrease in p–H3 after treatment with VX-680 ( lane 2 ) relative to controls ( lane 1 ) and an increase when SAHA was added ( lane 3 ). For the combination of VX-680 and SAHA (lane 4 ) no p-H3 was detected.

    Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck.

  • Vorinostat promotes C2C12 differentiation.In the image, the red is the myotube indicating differentiation ,the blue is the nuclei.

     

     

    Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM SAHA was added.

     

     

    Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Targets
HDAC [1]
(Cell-free assay)
~10 nM
In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. [1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. [2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. [3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A20 Mmj1T4lv[XOnIFHzd4F6 M13uWVEhcA>? MnG2SG1UVw>? NEnjVG5idnSrLVjERWMyKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEyOiEQvF2= NH3zZpUyOTl4MES4PS=>
Friend leukemic cell NFPSZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\WOVAh|ryP NGLn[lI4OiCq M3fFcmROW09? MlnsTWM2OD1yLkm5JO69VQ>? NYTuV5dSOTJzMEm5NVM>
K562 MXnLbY5ie2ViQYPzZZk> NI\McnM3KGh? MVjEUXNQ MmHTTY5pcWKrdHnvckBw\iCqdX3hckBpcXO2b37lJIRm[WOndInsZZNmKCivaYj0eZJmKG:oIFjERWMyKGGwZDDISGFEOilid3n0bEBKSzVyIH;mJFAvODFizszN NVjW[FdFOTJ2MUmzPFA>
HT1080 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jVb|czKGh? MVfEUXNQ M2XkZmlEPTB;Mj60JO69VQ>? MYixNlI4ODF5NR?=
H1299 MXvLbY5ie2ViQYPzZZk> M2HFb|IxKG2rbh?= M2LKZmROW09? NXnrU5IzUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KEiGQVOg[Y57gW2nIIfpeIghUUN3MDDv[kAxNjF7NDFOwG0> MVGxOFUzOTR{Mh?=
H1299 NETTVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XL[FczKGh? Moq0SG1UVw>? MonGTWM2OD15LkK0JO69VQ>? NFvZTGMyPDV{MUSyNi=>
HeLa MULLbY5ie2ViQYPzZZk> NGnYVpA{OCCvaX6= MUXJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqaYP0c45mKGSnYXPleJlt[XOnIIfpeIghUUN3MDDv[kAxNjJ6IN88US=> M{PUS|E2PjB|OUS5
LOX-IMVI NYH2N5dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnEOFghcA>? NI[4d4NKSzVyPUGuN{DPxE1? M1X1ZlE2PzF3NEew
NCI-H226 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPROFghcA>? M3zkRWlEPTB;Mj62JO69VQ>? NYX6NmxSOTV5MUW0O|A>
RXF-631L NGDEUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TwdFQ5KGh? M3nWbWlEPTB;MjFOwG0> MYCxOVcyPTR5MB?=
SNB-78 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfjVXV6PDhiaB?= MoHhTWM2OD1zNjFOwG0> NGLaTFEyPTdzNUS3NC=>
St-4 M4C4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvES3c1QCCq NG\mSWpKSzVyPUWuNkDPxE1? NFLzPYYyPTdzNUS3NC=>
ARP1 NIO4dpJHfW6ldHnvckBCe3OjeR?= M3fzOVIh|ryP NFrJUZU3KGh? NYPDW4E{UW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v NEHuXVcyPDd|NEiwOi=>
CEM MWjLbY5ie2ViQYPzZZk> M2nvelEhcA>? NYrLcI9LTE2VTx?= NVXkdndJUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM{KM7:TR?= M1:zVlE3PDJyME[0
HCT15 M3nINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzDWo01QCCq NIKwelhIUTVyPUCuPFIh|ryP M1roUVE3PzJ|MkK3
NCI-H23 M1\ZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\hOFghcA>? NV3nc446T0l3ME2wMlkzKM7:TR?= MXGxOlczOzJ{Nx?=
GM15850 MXTLbY5ie2ViQYPzZZk> NHXUZXEzNjVizszN NYLHV3JDQTZiaB?= MmH2SG1UVw>? NH\EOlJKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgNVQh[WOndInsZZRqd25ib3[gSnhPKGenbnW= MmTsNVY6OjF|Nke=
GM15850 NGXaXYtMcW6jc3WgRZN{[Xl? M{Ty[lIvPSEQvF2= MojaPVYhcA>? M3SySGROW09? MWDJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViNTDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>? MU[xOlkzOTN4Nx?=
GM15850 Mln2T4lv[XOnIFHzd4F6 NIruZ3IzNjVizszN MmLSPVYhcA>? MULEUXNQ M4TlXmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTCxNkBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?= NV23THlSOTZ7MkGzOlc>
GM15850 MXfLbY5ie2ViQYPzZZk> Mk[2Nk42KM7:TR?= MmO0PVYhcA>? MX\EUXNQ NYDXNGpjUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW= MmnSNVY6OjF|Nke=
GM15850 MXLLbY5ie2ViQYPzZZk> M{frR|IvPSEQvF2= M1fZR|k3KGh? MYHEUXNQ MoXhTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEigZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV? MmrENVY6OjF|Nke=
GM15850 MnvPT4lv[XOnIFHzd4F6 NUL3Um1POi53IN88US=> M2ezTlk3KGh? NULtNnptTE2VTx?= NXTLd2RJUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l MWexOlkzOTN4Nx?=
U937 MmPCSpVv[3Srb36gRZN{[Xl? NGDzWWg2KM7:TR?= MojHNlQhcA>? NI\Y[HJFVVOR NIftbW9E\WyuIHP5Z4xmKGG{cnXzeEBjgSCjY3P1cZVt[XSrb36gZZQhWy:JMj;NJJBp[XOn MU[xO|AxPDdzOB?=
H661 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjqS5E1QCCq MYTJR|UxRTFizszN M17K[FE4OTV5MEC5
U937 NUGyR3ZtTnWwY4Tpc44hSXO|YYm= NWDxN4h[PSEQvF2= M4faS|I1KGh? MYLEUXNQ M{PtbGlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36= NUOwO5FZOTd2NEe3OVA>
U937 NUfY[3N2TnWwY4Tpc44hSXO|YYm= NITvdVIyKM7:TR?= NEDEZ48zPCCq NXXNc4o5TE2VTx?= Mn;CSYZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36= NX\YZVBLOTd2NEe3OVA>
RAW264.7 NWXaUpcxTnWwY4Tpc44hSXO|YYm= NYHp[oE5OTBizszN MlTmNlRp MkTZe4F1\XJ? NX;ZSmk{UW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjd4IN88US=> NVHYUGxDOTd2N{e1NVg>
RAW264.7 MWfGeY5kfGmxbjDBd5NigQ>? NIDySnoyOCEQvF2= NWnNZ25WOjSq MmL6e4F1\XJ? MWHJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJG5QKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFEvQDhizszN M4HheVE4PDd5NUG4
SC9 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13NXFQ5KGh? NGHOb5JKSzVyPUCuOlA3KM7:TR?= MYOxO|UxPzJzOR?=
ST14A NX7jcGhJTnWwY4Tpc44hSXO|YYm= MYq1JI5O MYO3NkBp M{\4WWlv[3KnYYPlJIlvKFKHU2SvUnJUTiCvUl7BJIV5eHKnc4Ppc44> M2jkbFE4PTZ3OUmz
ST14A NI\QOmhHfW6ldHnvckBCe3OjeR?= MoTBOUBvVQ>? NGLNZ3A4OiCq MkPQTY5kemWjc3WgbY4hTTKIMTDtVm5CKGW6cILld5Nqd25? MmDzNVc2PjV7OUO=
PANC1 NEfFUIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHi[nYyKM7:TR?= NYTOfWVsUUN3ME2wMlQ2KM7:TR?= NH7oPVUyPzV6OEe0OC=>
PANC1 M2f3dWZ2dmO2aX;uJGF{e2G7 NXLLfXJOOSEQvF2= MWOyOEBp MXPJcoNz\WG|ZTDpckBxOjGZQV[xM2NKWDFiZ3Xu[UBmgHC{ZYPzbY9v NULrfGl2OTd3OEi3OFQ>
PANC1 M{PaUWZ2dmO2aX;uJGF{e2G7 NGG0ZW4yKM7:TR?= MX[yOEBp NUWwN3duUW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44> MUKxO|U5QDd2NB?=
PT45 NYO0T4NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTRizszN MkGwNVc2QDh5NES=
ACHN MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHmVIZDOjFiaB?= M2eyOmdKPTB;MD62OUDPxE1? MlXlNVc3PjJ4ME[=
PC3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv6NlEhcA>? MljjS2k2OD1yLkexJO69VQ>? MlHUNVc3PjJ4ME[=
A431 M1Lke2N6fG:2b4jpZ{BCe3OjeR?= Ml\DO|IhcA>? Ml63TWM2OD12LkKg{txO M1nuN|E4PjlzN{[z
Cal27 MofpR5l1d3SxeHnjJGF{e2G7 MXi3NkBp M2rsNWlEPTB;Mz6yJO69VQ>? M4jRfFE4PjlzN{[z
CCRF-CEM MmnLR5l1d3SxeHnjJGF{e2G7 NGHlTIQ4OiCq MlrDTWM2OD1yLkig{txO MWqxO|Y6OTd4Mx?=
EOL1 MkHXR5l1d3SxeHnjJGF{e2G7 NHG4PWw4OiCq NH;EcWZKSzVyPUGg{txO NYjLcGlIOTd4OUG3OlM>
Hec-1-A NVi3WFV[S3m2b4TvfIlkKEG|c3H5 NHHFSVE4OiCq NEHKe|NKSzVyPUGg{txO NH;3VXEyPzZ7MUe2Ny=>
HeLa MlvaT4lv[XOnIFHzd4F6 NF\q[Y0yOCEQvF2= NYrGbXVbOzBibXnu M3jTd2ROW09? MkL1TY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDISGFEOSC5aYToJGlEPTBib3[gNE4xOiEQvF2= NFfxUnAyPzZ7MUe2Ny=>
RKOp21 NYfKNWZ3S3m2b4TvfIlkKEG|c3H5 MVq3NkBp NWHnd2dZUUN3ME2xMlc3KM7:TR?= NYDGN3FsOTd4OUG3OlM>
Saos2 MlznR5l1d3SxeHnjJGF{e2G7 MmfXO|IhcA>? NXLvVXpPUUN3ME2yMlMh|ryP NEm5NooyPzZ7MUe2Ny=>
SK-OV-3 MnHSR5l1d3SxeHnjJGF{e2G7 MUi3NkBp M37ZbWlEPTB;Mj6yJO69VQ>? NYHkdGxHOTd4OUG3OlM>
U87MG MWDDfZRwfG:6aXOgRZN{[Xl? NUjobopCPzJiaB?= MYDJR|UxRTFzIN88US=> NFnLUpoyPzZ7MUe2Ny=>
NUGC3 M1LHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq1JO69VQ>? MYSyOEBp MYfHTVUxRTJwN{mg{txO MmnDNVc6ODR6NEO=
CCD1059SK NIryUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTR|LkWg{txO Ml:zNVgzPDd3NUS=
HepG2 M3fI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOwTWM2OD1yLkCwNFYh|ryP MmPmNVgzPDd3NUS=
HT1080 M{S1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjscmpKSzVyPUCuNFAzPCEQvF2= MXOxPFI1PzV3NB?=
SKBR3 M2XR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwODFOwG0> NInrbWcyQDJ2N{W1OC=>
SNB78 NXfUVIN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXFR|UxRTF4IN88US=> NEPRZ5UyQDJ2N{W1OC=>
SQ20B Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHTOGNKSzVyPUOg{txO MVOxPFI1PzV3NB?=
St4 NEf2dVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG5SWM2OD13LkKg{txO NEHv[FUyQDJ2N{W1OC=>
MCF7 NIfKVohHfW6ldHnvckBCe3OjeR?= NIfzeGoyOCEQvF2= NX7RN3BUQCCq MWjEUXNQ NVvXcmVyUW6mdXP0bY9vKG:oIIT1ZpVtcW5iaInw[ZJi[2W2eXzheIlwdg>? MYSxPFI3QTJ{Nh?=
HEK293 MYXLbY5ie2ViQYPzZZk> M1fGTlEhcA>? MUDEUXNQ MWLJcohq[mm2aX;uJI9nKEiGQVOxJJdqfGhiSVO1NEBw\iByLkCzJO69VQ>? MWexPFMxQDV4Mx?=
HEK293 M36yPGtqdmG|ZTDBd5NigQ>? NY\MNXdmOSCq NHTYeXpFVVOR NEjiXmFKdmirYnn0bY9vKG:oIFjERWM{KHerdHigTWM2OCCxZjCwMlA2PyEQvF2= M4\UXVE5OzB6NU[z
G401 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[5NXc4OiCq MoLvSG1UVw>? NF7DeoVKSzVyPUGg{txO MWGxPFM4ODN5Mx?=
HeLa NYO2To14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjuTJk4OiCq NXXOW204TE2VTx?= M1jCWWlEPTB;MD60OkDPxE1? MXuxPFM4ODN5Mx?=
Human renal epithelial cell MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT5V5hRPzJiaB?= MV7EUXNQ NFSwZ5hKSzVyPUG0JO69VQ>? NWXEVFFxOTh|N{CzO|M>
U937 MYTGeY5kfGmxbjDBd5NigQ>? NHe4eXY2KM7:TR?= NIDsXoozPCCq NFjoV|hKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKNDDofZBmemGlZYT5cIF1cW:w MnPvNVg{QDF{M{i=
U937 NFvjXHNHfW6ldHnvckBCe3OjeR?= M2n6VVUh|ryP MYqyOEBp MW\JcoR2[3Srb36gc4Yh[WyyaHGgeJVjfWyrbjDofZBmemGlZYT5cIF1cW:w NGKyPYoyQDN6MUKzPC=>
U937 MmDnSpVv[3Srb36gRZN{[Xl? MX:1JO69VQ>? M2KyXVI1KGh? M2nvTGlv\HWldHnvckBw\iCyMkGg[ZhxemW|c3nvci=> NWrqc|VOOTh|OEGyN|g>
U937 MoHYSpVv[3Srb36gRZN{[Xl? NIPDR3Q2KM7:TR?= MVuyOEBp NVvR[Fh4UW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= M1Swb|E5OzhzMkO4
U937 MlK3SpVv[3Srb36gRZN{[Xl? NHHFZYo2KM7:TR?= NUHRbG4zOjRiaB?= MXvJcoR2[3Srb36gc4Yh\3KjboXsc4N6fGmlIHTp[oZmemWwdHnheIlwdg>? NYLkbIxyOTh|OEGyN|g>
U937 MXvLbY5ie2ViQYPzZZk> NIDyTYs2KM7:TR?= NF3sSm4zPCCq MXvJcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNz NITWTGUyQDN6MUKzPC=>
U937 M4XGb2tqdmG|ZTDBd5NigQ>? NEHqZoo2KM7:TR?= NFLTcHAzPCCq NGTPPFZKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO0 MnzBNVg{QDF{M{i=
HEK-TE MnfOSpVv[3Srb36gRZN{[Xl? M4S3[lUh|ryP NFjpOHI3cA>? MUPEUXNQ NXzFVnZ2UW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDhZ4V1gWyjdHnvci=> NUL4UJdzOTh2M{SxOFQ>
HPDE6c7 NE\5dmVEgXSxdH;4bYMhSXO|YYm= NGiyNI42OCEQvF2= Mo[zO|IhcA>? NVT4bGFKTE2VTx?= NInTXldKSzVyPUGuN{DPxE1? M4[1W|E5PDl2NE[z
Human microvascular epithelial cell MXrDfZRwfG:6aXOgRZN{[Xl? MWS1NEDPxE1? M2L6b|czKGh? M1\MSGROW09? MkH5TWM2OD1zLkOg{txO MmiwNVg1QTR2NkO=
Hup T3 M{HtcGN6fG:2b4jpZ{BCe3OjeR?= NF25VmU2OCEQvF2= MnrrO|Jp MoXUSG1UVw>? NVTtWGo6UUN3ME2wMlgh|ryP MVWxPFQ6PDR4Mx?=
Mia Paca2 MoPTR5l1d3SxeHnjJGF{e2G7 Ml64OVAh|ryP M4L2OFczcA>? M3m2U2ROW09? NXvUOGF[UUN3ME2xMlEh|ryP M1XORVE5PDl2NE[z
Panc 04.03 MkTNR5l1d3SxeHnjJGF{e2G7 MmnuOVAh|ryP M3TtNFczcA>? MmWzSG1UVw>? MoTpTWM2OD1zLkKg{txO MWSxPFQ6PDR4Mx?=
SU 86.86 NVLHTGlES3m2b4TvfIlkKEG|c3H5 MYO1NEDPxE1? NVTifXp4PzKq MWjEUXNQ MlyyTWM2OD1zLkOg{txO NYS3[oVyOTh2OUS0OlM>
HEK293 NF7Y[lFMcW6jc3WgRZN{[Xl? NGfZZZQ{KGh? NWLrfIhEUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJTEGFNjDlfJBz\XO|aX;uJJdqfGhiSVO1NEBw\iByLkCxPUDPxE1? MnztNVg2PTh4Nkm=
HeLa NXHxWHNCU2mwYYPlJGF{e2G7 M2H6TlIhcA>? MnrBTY5pcWKrdHnvckBw\iCwdXPs[YFzKEiGQVOge4l1cCCLQ{WwJI9nKDBwMEizJO69VQ>? M1rsb|E5PTV6Nk[5
RAW264.7 NVW5NnZWTnWwY4Tpc44hSXO|YYm= NYTmc3RiOiEQvF2= Mkj5N{42KGh? NYnzeYlnTE2VTx?= M1;G[mFvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDpcoZm[3SnZDD3bZRpKEmFNUCgc4YhOC5zMTFOwG0> NWO3SJhsOTh4NES5Olk>
NB4 NH3UUJc1QGh? M4XDSGROW09? MVvJR|UxRTBwNjFOwG0> NVzheIN[OTh5MkOzOFk>
HEK293 MUjGeY5kfGmxbjDBd5NigQ>? NGnk[lEyOCEQvF2= NHv4W2IzPCCq NY\TNmRHTE2VTx?= Ml;SRYN1cX[jdHnvckBw\iCvb4Xz[UBYdnR|YTDzbYdv[Wyrbneg[ZhxemW|c3Xk NYLoNWdvOTlyMkK2O|U>
HCT116 MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LOUlczcA>? M3zlU2ROW09? MYDJR|UxRTBwM{Gg{txO MX:xPVA5PDJ7NB?=
HeLa MYnLbY5ie2ViQYPzZZk> Ml\aNkDPxE1? MlvnN|AhdWmw NUPNcGx3TE2VTx?= MmS1TY5pcWKrdHnvckBw\iCKRFHDNkBqdiCqdX3hckBJ\UyjIHPlcIx{KHerdHigTWM2OCCxZjCwMlEh|ryP NEDJb2gyQTB6NEK5OC=>
IGROV1 M1zhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHhVHM4PzJiaB?= MYDEUXNQ NYTKXHlRUUN3ME2yMlIh|ryP NYX3[XIxOTlyOESyPVQ>
IGROV1 M2n3fWtqdmG|ZTDBd5NigQ>? NIiwZlA2KM7:TR?= M3XIfVI1KGh? NHLMNnNFVVOR MmjWTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KHB3MzDhZ4V1gWyjdHnvci=> Mlm2NVkxQDR{OUS=
IGROV1 M1HOdmtqdmG|ZTDBd5NigQ>? Mk\oNVAh|ryP MoKwOEBp Mnz1SG1UVw>? MmX2TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGirc4TvcoUuUDRiYXPleJlt[XSrb36= MoXlNVkxQDR{OUS=
IGROV1 MlXQT4lv[XOnIFHzd4F6 MnLaNVAh|ryP M2DVeVQhcA>? NIe1OlVFVVOR MUTJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W|c3XkJIF{KGGucHjhMZR2[nWuaX6gZYNmfHmuYYTpc44> MU[xPVA5PDJ7NB?=
T24 M{\4OGtqdmG|ZTDBd5NigQ>? MlrtN{Bp M{G1TWlv\HWldHnvckBw\iCqaYP0c45mKEh|IHHj[ZR6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGyJO69VQ>? NWfMVFhpOTlyOESzPVU>
T24 MmrwT4lv[XOnIFHzd4F6 NHnYeJI{KGh? NYjLRlRzUW6mdXP0bY9vKG:oIHHsdIhiKHS3YoXsbY4h[WOndInsZZRqd25id3n0bEBGSzVyIH;mJFAvOjVizszN NXrqPVgyOTlyOESzPVU>
HeLa MWPLbY5ie2ViQYPzZZk> NHXTNVQyPSCvaX6= Mo\DSG1UVw>? MlnFTY5pcWKrdHnvckBw\iCKRFHDOkBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNE4xQDV3IN88US=> NUnYWIxvOTlyOUO4PFQ>
HeLa MWjLbY5ie2ViQYPzZZk> MkG2NVUhdWmw NU\HO5NkTE2VTx?= Mom1TY5pcWKrdHnvckBw\iCKRFHDPEBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNU45PiEQvF2= MV[xPVA6Ozh6NB?=
NCI-H69 MVPDfZRwfG:6aXOgRZN{[Xl? M4r5[|czKGh? NXjKXY9{TE2VTx?= MmnKTWM2OD1{LkC2JO69VQ>? NIWxXW8yQTB7M{i4OC=>
SKMES1 NY\0dI8zS3m2b4TvfIlkKEG|c3H5 MYS3NkBp NYSyV2NPTE2VTx?= M{LwOGlEPTB;Mj60NkDPxE1? MkC5NVkxQTN6OES=
S2 MVXLbY5ie2ViQYPzZZk> MVmwMlEuOTBizszN MUmxJIg> NEHEdHpKdmirYnn0bY9vKG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBJTEGFMTDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMEW5JO69VQ>? MWOxPVMyPzR3MB?=
SHSY5Y MojkT4lv[XOnIFHzd4F6 M3PmWVExKM7:TR?= M3e5blQ5KGh? MkDJSG1UVw>? NF7IOW5KdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOUDPxE1? M372WFE6OzR2MUe1
SHSY5Y NYLlTpF3S3m2b4TvfIlkKEG|c3H5 M3vYclExKM7:TR?= MoPxOFghcA>? NHv4bpFFVVOR MVTJR|UxRTJizszN NVm1[YhyOTl|NESxO|U>
DMS114 NIO5SYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme0OFghcA>? NELBV3RIUTVyPUKuPUDPxE1? NG\EXG4yQTRzOUKwOS=>
HBC5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK1em01QCCq M{LoV2dKPTB;MUeg{txO NYe0T2JiOTl2MUmyNFU>
SNB78 NWTrV3BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\hR4w1QCCq MnjxS2k2OD1zNjFOwG0> NYD2VI1SOTl2MUmyNFU>
HeLa M4W1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP1O|IhcA>? MkG1SG1UVw>? MWDJR|UxRTBwNE[g{txO MYWxPVQ1OTh2Nh?=
BHK MUjLbY5ie2ViQYPzZZk> Mn[5OUDPxE1? MYGyOEBp M1rPeWROW09? M3LudmlvcGmkaYTpc44hd2ZiSFTBR|ch\XiycnXzd4VlKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJBt[XOvYTDt[Y1jemGwZTDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv MWmxPVk3Pjd6OR?=
CFBE41o- MUjLbY5ie2ViQYPzZZk> NHHOOIo2KM7:TR?= MlXGPEBp NGfSbGVFVVOR NH3Tc3hKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaInw[ZJi[2W2eXzheIlwdiCxZjDobZN1d26nIFiz M4LpZVE6QTZ4N{i5
CFBE41o- MW\LbY5ie2ViQYPzZZk> NXLNcoMzPSEQvF2= MkjkOEBp Mm\CSG1UVw>? MmrYTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIH31eIFvfCCIZHXseIE2ODhiQ1\UVkBxem:2ZXnuJIxmfmWu MVWxPVk3Pjd6OR?=
CFBE41o- NETMc5FMcW6jc3WgRZN{[Xl? NX\0OpZFOSEQvF2= MmDDNUBp M3zpVmROW09? M4\vUWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDDSnRTKHC{b4TlbY4hdGW4ZXy= NYPYR3N6OTl7Nk[3PFk>
Primary bronchial epithelial cell M4jNfmtqdmG|ZTDBd5NigQ>? NEj4b3IyKM7:TR?= M1O5PFI1KGh? NELMTZZFVVOR MVnJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBieGmlYXygd5Vz\mGlZTDsc4NidGm8YYTpc44> M1LJclE6QTZ4N{i5
CFBE41o- MnzFT4lv[XOnIFHzd4F6 NYOzOWdDOSEQvF2= NEfuVWk2KGSjeYO= NGDMT|NFVVOR Mn70TY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzeIFjcWyrenH0bY9vKG:oIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4> NXXQNHJIOTl7Nk[3PFk>
CFBE41o- MmLWT4lv[XOnIFHzd4F6 NICxfGYyKM7:TR?= M4jmWFI1KGh? NICyTWxFVVOR NGLWOZBKdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5idILh[oZq[2urbne= MWCxPVk3Pjd6OR?=
CFBE41o- NEL0b5FMcW6jc3WgRZN{[Xl? M2TqSlUh|ryP NXvoe5hlOjRiaB?= NWHMRnduTE2VTx?= NWfOdZJKUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBz[XSnIH;mJI1ifHW{YYTpc44hd2ZiQ1\UVkBxem:2ZXnuJJRwKGm2czDncJlkd2[xcn2= NH;xXlQyQTl4Nke4PS=>
CFBE41o- NX7jOJVLU2mwYYPlJGF{e2G7 NGO0XVk2KM7:TR?= NXe2SZpPOjRiaB?= NXPo[pA5TE2VTx?= MYLJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm2eTDv[kBH\GWudHG1NFghS0[WUjDwdo91\Wmw NUfZVIFyOTl7Nk[3PFk>
CFBE41o- MWLLbY5ie2ViQYPzZZk> M1HqfVUh|ryP MUiyOEBp NVvP[pBYTE2VTx?= M4XPNGlvcGmkaYTpc44hd2ZiSFTBR|ch[XO|ZYPz[YQh[XNiY3;ydoVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJidILh[oZq[2urbnegeI8h[2WubDDzeZJn[WOnIHHzJIdtgWOxZn;ycS=> Mk[5NVk6PjZ5OEm=
Primary bronchial epithelial cell NV75SlcxU2mwYYPlJGF{e2G7 NYHMUFRQPSEQvF2= M3rLfFI1KGh? MXLEUXNQ M4nqSGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v NIHnfXMyQTl4Nke4PS=>
Primary bronchial epithelial cell NFTWXZFMcW6jc3WgRZN{[Xl? M1fPcFEh|ryP MlXEPVYhcA>? MmC1SG1UVw>? M2jLTmlvcGmkaYTpc44hd2ZiSFTBR|ch[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gd4hwenRiY3nyZ5VqfCCldYLy[Y51ew>? M1jocFE6QTZ4N{i5
BxPC3 NWTaN4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfiO|IhcA>? NXTxO4h2UUN3ME2yMlch|ryP M2PkbFIxOTR|N{e4
CAL27 NEjFR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3NkBp Mk\mTWM2OD1|LkeyJO69VQ>? NHO1[pIzODF2M{e3PC=>
Capan1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y1SlczKGh? MlziTWM2OD15LkOg{txO MoezNlAyPDN5N{i=
HCC827 NGmzVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vhOlczKGh? Mlr1TWM2OD1zLkig{txO M2HTVFIxOTR|N{e4
LNCAP NWD0WmNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:5OohyPzJiaB?= NFnmW2RKSzVyPUCuOVgh|ryP NV7SSlN6OjBzNEO3O|g>
NCI-H2122 MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfmO|IhcA>? NGHKb|NKSzVyPUeuOUDPxE1? NXvxXVJrOjBzNEO3O|g>
NCI-H358 NH;6bolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Tn[FczKGh? MYjJR|UxRTJwNTFOwG0> M1LuUlIxOTR|N{e4
SCC15 MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVq3NkBp M{n1bmlEPTB;Mj60PUDPxE1? NHXrXY4zODF2M{e3PC=>
SCC25 M3zzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j5RVczKGh? M{[5N2lEPTB;MT65N{DPxE1? M4\GR|IxOTR|N{e4
SKHEP1 NF3CfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe2cXU4OiCq MX3JR|UxRTNwNE[g{txO MVmyNFE1Ozd5OB?=
BJ NXHGW2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqxNFAh|ryP NWn1b29bPDhiaB?= MlrnSG1UVw>? MX\Hdo94fGhiaX7obYJqfGmxbjDheEAxNjB3IITvJFExOCC3TR?= MYiyNFE1Ozh2MB?=
MUF M2rCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnriNVAxKM7:TR?= MUG0PEBp NYS2b2lKTE2VTx?= M3rzU2dzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN NHnXTYgzODF2M{i0NC=>
Caco-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\WPWEyODBizszN Mme4OFhp M3zRV2ROW09? M3\pVmlEPTB;OD6xJO69VQ>? NWfUPGF3OjBzNEO4OFA>
Caco-2 NF3HN4xMcW6jc3WgRZN{[Xl? NFLqN4w2KM7:TR?= M2OwT|QhcA>? M2\VSWROW09? NGnMZZBKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIFk\XS7bHH0bY9vKEmFNUCgc4YhOC5yM{eg{txO MXiyNFE1Ozh2MB?=
Caco-2 MYHLbY5ie2ViQYPzZZk> M1HMfVAvOzF4IH7NJJRwKDNzLk[g{txO MYO0JIg> MYLEUXNQ M2jzRmV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMTD3bZRpKEmFNUCgc4YhOC5zMUmg{txO NUOxTVU5OjBzNEO4OFA>
Caco-2 NIXzRYxMcW6jc3WgRZN{[Xl? M4Lo[VAvOzF4IH7NJJRwKDNzLk[g{txO Mn;vOEBp MVXEUXNQ MkOySZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN|IIfpeIghUUN3MDDv[kAxNjF2NzFOwG0> NUT3UFJoOjBzNEO4OFA>
Caco-2 MYLLbY5ie2ViQYPzZZk> M4fSOVYvOzJibl2geI8hPjN{IN88US=> M4X5eFQhcA>? MW\EUXNQ MnPVSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN3IIfpeIghUUN3MDDv[kAyOi54IN88US=> MWCyNFE1Ozh2MB?=
Caco-2 NW[yT2lnU2mwYYPlJGF{e2G7 NFzlNI83NjN{IH7NJJRwKDZ|MjFOwG0> M3TF[FQhcA>? NVXOXGZHTE2VTx?= Mn;2SZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN5IIfpeIghUUN3MDDv[kA1OSEQvF2= MlT3NlAyPDN6NEC=
Caco-2 M1[yV2tqdmG|ZTDBd5NigQ>? M4X1UlAvOzF4IH7NJJRwKDNzLk[g{txO MljaOEBp MlXOSG1UVw>? M4jz[WV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNh?= NFr0dIszODF2M{i0NC=>
HepG2 MWHLbY5ie2ViQYPzZZk> M3i4WFUh|ryP NVfPPW9bPmh? MVPEUXNQ MmCxTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDhZ4V1gWyjdHnvci=> NU\Menc{OjBzNEO4OFA>
HepG2 MlnkT4lv[XOnIFHzd4F6 MX:1JO69VQ>? M3S3cFZp MVvEUXNQ NHXvNZJKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIh6eGW{YXPleJlt[XSrb36= NWDGWZhiOjBzNEO4OFA>
HepG2 M2DacWtqdmG|ZTDBd5NigQ>? NXHxbYpKPSEQvF2= NXX5NYdwPmh? NXrib2RoTE2VTx?= NWDiO4xjUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=> Ml3lNlAyPDN6NEC=
HepG2 NF3YeZVMcW6jc3WgRZN{[Xl? MmXYOUDPxE1? M1m5T|Zp NF3FWGpFVVOR M2C4bWlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJGg{N0h2IHjpd5RwdmViYXPleJlt[XSrb36= M1nvU|IxOTR|OESw
COLO205 MmnCT4lv[XOnIFHzd4F6 NYPRZlFxOTBizszN MoO1NlQhcA>? MXXEUXNQ MmLoTY5pcWKrdHnvckBw\iCKRFHDNUBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdiC5aYToJGlEPTBib3[gNk4zKM7:TR?= MkDVNlA1PTF|N{i=
SCC4 Mo\RT4lv[XOnIFHzd4F6 MWexJO69VQ>? NVjvTmFuOjSq MkHETY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIT1ZpVtcW5iYXPleJlt[XSrb36= M1PnelIxPDV{MkK1
SCC4 MXXLbY5ie2ViQYPzZZk> MUGxJO69VQ>? M3fDVVI1cA>? NH\OWWRKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDhZ4V1gWyjdHnvci=> MlrFNlA1PTJ{MkW=
SCC4 M3\2VWZ2dmO2aX;uJGF{e2G7 NWPGbJdrOSEQvF2= MUm1JI1qdg>? NGnMUGJC\2:waYP0JIFkfGm4aYT5JIF1KF[GUjDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiQ2nQNlQh\2WwZTDlfJBz\XO|aX;u MmWwNlA1PTJ{MkW=
NB4 MlzNSpVv[3Srb36gRZN{[Xl? MmnIOUDPxE1? NWLQWnJqOjRiaB?= NX\QPG5YTE2VTx?= NH\TNmdE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44h[XRicILlMWcyKHCqYYPl M2rrdFIxPDlzNESw
NB4 MoTTT4lv[XOnIFHzd4F6 NGro[Yk2KM7:TR?= MmS1NlQhcA>? M1HXZmROW09? M1jNcWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWyjdHWgeJVjfWyrbjDs[ZZmdA>? M2XGblIxPDlzNESw
NB4 MUHGeY5kfGmxbjDBd5NigQ>? M{nzXFUh|ryP MWCyOEBp NIrIVWtFVVOR NUTkW5l2UW6mdXP0bY9vKG:oIICyNXdCTjFxQ1nQNUBmgHC{ZYPzbY9v MXOyNFQ6OTR2MB?=
NB4 NEHyXI9McW6jc3WgRZN{[Xl? NXzKPJlTPSEQvF2= NHHsZ3IzPCCq MoC3SG1UVw>? M3HrR2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIFk\XS7bHH0bY9v M4jFcFIxPDlzNESw
NUGC3 NGGxU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfwNGRIUTVyPUKuPVQh|ryP NEC3b3czODh3MEm3NS=>
A549 MVrGeY5kfGmxbjDBd5NigQ>? MnTvOUDPxE1? M1:1WlMhcA>? NXPHSJd7TE2VTx?= M4TLdWlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=> NUTVZWRzOjB6NUWyNFg>
HUT78 M{nWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfMdZM4OiCq MYnEUXNQ M33tUmdKPTB;MD6zJO69VQ>? M1\GW|IxQDh2MkC4
U937 M2XnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHOO|IhcA>? NWO2VHhoTE2VTx?= M1\HZmdKPTB;MD6zPUDPxE1? NYHoWmtZOjB6OESyNFg>
A431 NVjNW2pQS3m2b4TvfIlkKEG|c3H5 MUW3NkBp MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR|UxKG:oIESuNkDPxE1? NYn3cFNmOjFyOEC2Nlk>
A549 NHX2OY1EgXSxdH;4bYMhSXO|YYm= NGXnVG44OiCq M17qUGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMhd3[ncnX4dJJme3OrbnegTGRCSyC5aYToJGlEPTBib3[gNU45KM7:TR?= MUeyNVA5ODZ{OR?=
CAL27 M1K3c2N6fG:2b4jpZ{BCe3OjeR?= MWW3NkBp MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDRWwzPyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKHerdHigTWM2OCCxZjCzMlIh|ryP NEnifoszOTB6ME[yPS=>
HeLa M4XmOWN6fG:2b4jpZ{BCe3OjeR?= Mn3MO|IhcA>? MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJI93\XKneIDy[ZN{cW6pIFjERWMhf2m2aDDJR|UxKG:oIEGuOUDPxE1? NGrCT2QzOTB6ME[yPS=>
Sf21 NWrCdWhYU2mwYYPlJGF{e2G7 NUL0S29[OyCq M3XQS2lvcGmkaYTpc44hd2ZiRnzh[{B1[WepZXSgbJVu[W5icnXjc41jcW6jboSgTGRCSzhiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAyNjJizszN NVPMW|c5OjFyOEC2Nlk>
SKBR3 NYnXfoVTS3m2b4TvfIlkKEG|c3H5 MoTKO|IhcA>? M2O3NGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMSlJ|IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGhGWjJid3n0bEBKSzVyIH;mJFIvPiEQvF2= Mm\5NlExQDB4Mkm=
SKOV3 MmL4R5l1d3SxeHnjJGF{e2G7 NV3K[24zPzJiaB?= MmnIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk4zKM7:TR?= MWmyNVA5ODZ{OR?=
COR-L23 NHzqVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIq1NpIyOCEQvF2= Mk\BO|IhcA>? MWLEUXNQ NFey[2VIUTVyPUGuNUDPxE1? M3zXeFIyODhyNkS3
DU145 NHmxVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfxeXEyOCEQvF2= NEHlbW04OiCq NYK3XG17TE2VTx?= NWD6doFPT0l3ME2xMlA2KM7:TR?= MUSyNVA5ODZ2Nx?=
LoVo NYrrd2FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3aPWt5OTBizszN M{HtXFczKGh? NVe4N3c5TE2VTx?= MWrHTVUxRTFwNzFOwG0> MUSyNVA5ODZ2Nx?=
MCR5-SV2 NInWb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSyPVRYOTBizszN NX\oUpdRPzJiaB?= NYDmOXNlTE2VTx?= NFTFOXBIUTVyPUKuNUDPxE1? NHm4dZQzOTB6ME[0Oy=>
HCT116 NH3xXIJMcW6jc3WgRZN{[Xl? MXqzNEDPxE1? NXHzcHRWOzBiaB?= NY\hZ|ViTE2VTx?= MWnJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w NFPUdlAzOTB6ME[0Oy=>
HCT116 NETOTWZMcW6jc3WgRZN{[Xl? NXTsdHF7OzBizszN MlfHN|AhcA>? MlLuSG1UVw>? MlvuTY5pcWKrdHnvckBw\iCKRFHDNUBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gbIl{fG:wZTDIN2s6KGGlZYT5cIF1cW:w MlfQNlExQDB4NEe=
U937 NWCwWotnU2mwYYPlJGF{e2G7 M4LKZVUh|ryP NXfPcYNNOjRiaB?= NV7ZRY8{TE2VTx?= MYXJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO|ZYPz[YQh[XNiaX7jdoVie2Vib3[gZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMzDheEBMQQ>? MkjBNlEzQTJ2OUK=
U937 NVPBTnhNU2mwYYPlJGF{e2G7 M{PVdFUh|ryP M{fLUlI1KGh? NFrqNY9FVVOR NX2wbox2UW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{G4 MkfqNlEzQTJ2OUK=
U937 Mk[zT4lv[XOnIFHzd4F6 NEL5Zoc2KM7:TR?= MUGyOEBp MXLEUXNQ MlvRTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJJBidi2jY3X0fYxifGWmIHjpd5RwdmViSESgcIV3\Wx? M4juU|IyOjl{NEmy
U937 NIHmdWJMcW6jc3WgRZN{[Xl? NGXubJI2KM7:TR?= MkDnNVUhdWmw NXzM[4tvTE2VTx?= MnrUTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25ibHX2[Yw> NYLaUY84OjF{OUK0PVI>
A2780 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXKUJFKQTZiaB?= NHvS[GJFVVOR MWrJR|UxRTFwNkKg{txO M1eySVIyPjN2NEOw
COLO205 NEP6dIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv1O5JyQTZiaB?= MnjlSG1UVw>? MljhTWM2OD1{LkGyJO69VQ>? MXyyNVY{PDR|MB?=
Hep3B MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DZbFQ5KGh? NEDNflhFVVOR MoXGS2k2OD1zLkKxJO69VQ>? MoXwNlE4OTJzNE[=
GM11272 MVjGeY5kfGmxbjDBd5NigQ>? NFLtPFQyODBibl2= NWize2NGPzJiaB?= M1jIW2ROW09? MYLS[YFkfGm4YYTpc44hd2ZiTXXDdFIhdXW2YX70JIV5eHKnc4Ppc44h[XRiMUCgeI8hOTByIH7N MY[yNVg1ODdzNh?=
CFBE41o MXHLbY5ie2ViQYPzZZk> NFyx[2o2KM7:TR?= NVrWNYlrTE2VTx?= MXfEc5dvKHKnZ4XsZZRqd25ib3[gTGRCSzdiYYSgNE4zKHSxIEWgeW0> NE\yNowzOTl6NEm1PC=>
CFBE41o MmTYSpVv[3Srb36gRZN{[Xl? MmPFNUDPxE1? M1Tmd|I1KGh? MoPmSG1UVw>? NEDEcZlT\XO2b4LheIlwdiCxZjDDSnRTKGSnbIThSlUxQCCvdYThcpQhfHKjZn\pZ4tqdmdidH:gZ4VtdCC|dYLmZYNmKGG|IHfsfYNw\m:{bYO= NUPueY45OjF7OES5OVg>
DU145 MVPLbY5ie2ViQYPzZZk> MoLDNk42KM7:TR?= NFjsbHYzPCCq MUPEUXNQ M3HlN2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YheDJzd3HmNUBxem:2ZXnuJIV5eHKnc4Ppc44> NYG3cmdHOjJ{NkCxOlY>
DU145 NH\DNXJMcW6jc3WgRZN{[Xl? NIfNfGQ2KM7:TR?= NF2yTnQzPCCq NFTuO4ZFVVOR Mn2yTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGirc4TvcoUhUDRiYXPleJlt[XSrb36= MUGyNlI3ODF4Nh?=
DU145 MXrLbY5ie2ViQYPzZZk> MVW1JO69VQ>? MkDiNlQhcA>? MWHEUXNQ M{\5fGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mKEh|IHj5dIVz[WOndInsZZRqd25? NGr0coQzOjJ4MEG2Oi=>
786-0 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXxZ3Q3NjJizszN NIjnb|A4OiCq M4DiXmROW09? MmDCS2k2OD1|LkKg{txO M2nRd|IzPDN3Nk[5
A498 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M136Z|YvOiEQvF2= MX63NkBp MlznSG1UVw>? M1vkN2dKPTB;MT62JO69VQ>? NFvIXnczOjR|NU[2PS=>
A549/ATCC M3zQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jv[VYvOiEQvF2= MmW4O|IhcA>? MWrEUXNQ M2Tib2dKPTB;MT62JO69VQ>? Mmr3NlI1OzV4Nkm=
ACHN M13m[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK2MlIh|ryP MXi3NkBp NIPNfHVFVVOR M3fsTGdKPTB;MT6zJO69VQ>? NYfp[o9OOjJ2M{W2Olk>
BT549 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO2MlIh|ryP M{\sRlczKGh? MkDlSG1UVw>? NHX4XYVIUTVyPUGuN{DPxE1? MkHrNlI1OzV4Nkm=
EKVX MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PYfFYvOiEQvF2= NXPyOmZOPzJiaB?= M1LI[WROW09? MYfHTVUxRTFwMzFOwG0> M{HLUVIzPDN3Nk[5
HCT15 NVz6dphuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnSTXU3NjJizszN MmW5O|IhcA>? MY\EUXNQ Ml3SS2k2OD1{LkWg{txO M370NFIzPDN3Nk[5
HOP92 NYXJUplYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTDOk4zKM7:TR?= MYG3NkBp M{HZVWROW09? M1LOV2dKPTB;NDFOwG0> NXexNI5KOjJ2M{W2Olk>
IGROV1 M3HyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVflT4lGPi5{IN88US=> MkXyO|IhcA>? NYqyN|JwTE2VTx?= MUDHTVUxRTFwMzFOwG0> MWqyNlQ{PTZ4OR?=
LOXIMVI NY\GN3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fyXlYvOiEQvF2= MV:3NkBp M3j0SWROW09? Mn;6S2k2OD1zIN88US=> MXOyNlQ{PTZ4OR?=
M14 M{TXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUC2MlIh|ryP M4m5XlczKGh? MmTVSG1UVw>? NGr0d5dIUTVyPUGuN{DPxE1? MWCyNlQ{PTZ4OR?=
MALME-3M NGfPclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjNfWEzPi5{IN88US=> MnHVO|IhcA>? M1XsbWROW09? MXfHTVUxRTBwM{Kg{txO NFS1flYzOjR|NU[2PS=>
MCF10A MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImxSWQ3NjJizszN NFjGd|E1QCCq MYnEUXNQ MmrSS2k2OD17Lk[g{txO MY[yNlQ{PTZ4OR?=
MDA-MB-435 M{SzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGGyXZM3NjJizszN NWH2UJoxPzJiaB?= MlraSG1UVw>? MlThS2k2OD1yLkWg{txO NXrB[4JOOjJ2M{W2Olk>
MDA-MB-468 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv2VGk3NjJizszN Mn\HO|IhcA>? M1fXdWROW09? M2XiN2dKPTB;MD62N{DPxE1? NFGwd28zOjR|NU[2PS=>
MOLT4 NI\tdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfwbZhiPi5{IN88US=> NIHQcIg4OiCq NUP3eGozTE2VTx?= M4nkdWdKPTB;MD60JO69VQ>? NWnTb3NROjJ2M{W2Olk>
NCI-ADR-RES MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHIU|dyPi5{IN88US=> MVW3NkBp M3zjZ2ROW09? MYfHTVUxRTBwMU[g{txO MmixNlI1OzV4Nkm=
NCI-H23 M33u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\PTlc3NjJizszN NHHVfYU4OiCq NHHwOYxFVVOR NInhU5JIUTVyPUGg{txO NHPl[FczOjR|NU[2PS=>
NCI-H322M NEjQeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jjXFYvOiEQvF2= MYW3NkBp MX3EUXNQ NIm5b5lIUTVyPUCuO|kh|ryP M13MNVIzPDN3Nk[5
NCI-H460 M2npNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXFUWJ[Pi5{IN88US=> NXzudJRYPzJiaB?= NHLucXVFVVOR M4m1PWdKPTB;MD63PUDPxE1? MXKyNlQ{PTZ4OR?=
NCI-H522 NH65VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nJOFYvOiEQvF2= NFTIb5o4OiCq NVW2[nV4TE2VTx?= NH7tWVdIUTVyPUCuOUDPxE1? MoXQNlI1OzV4Nkm=
OVCAR3 MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XkT|YvOiEQvF2= NWXQe5d[PzJiaB?= NUSwT5d7TE2VTx?= NWe4Uo1XT0l3ME2xMlMh|ryP NHfYfpYzOjR|NU[2PS=>
OVCAR4 M3v6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXxXHM3NjJizszN Mne0O|IhcA>? M4rGbGROW09? M{L1N2dKPTB;NDFOwG0> MlGxNlI1OzV4Nkm=
OVCAR5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYK2MlIh|ryP NUO2NJBiPzJiaB?= M4rHNWROW09? M{C2TGdKPTB;MD63PUDPxE1? MoLwNlI1OzV4Nkm=
OVCAR8 NFn0SJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTvOk4zKM7:TR?= MmHFO|IhcA>? M3fDUWROW09? Mnq1S2k2OD1yLkWg{txO NVnPZYU4OjJ2M{W2Olk>
RXF393 NHf0blJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvzVpBJPi5{IN88US=> NIDx[2Q4OiCq NVLufmdjTE2VTx?= NGPrWpZIUTVyPUGuN{DPxE1? NITBZmozOjR|NU[2PS=>
SF268 M{ewUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVu2MlIh|ryP M3\T[lczKGh? NULPPHQ3TE2VTx?= MlrHS2k2OD1zLk[g{txO NGG2e4YzOjR|NU[2PS=>
SF295 NYrieZhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUi2MlIh|ryP MYS3NkBp M2PEemROW09? NUnLSGF[T0l3ME2xMlYh|ryP MmGyNlI1OzV4Nkm=
SF539 NGHpeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS2MlIh|ryP M37LTFczKGh? NY\SeVhMTE2VTx?= M1f0O2dKPTB;MjFOwG0> NWruXlZSOjJ2M{W2Olk>
SK-MEL-2 NIPrc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:2MlIh|ryP NULLWJVnPzJiaB?= MXXEUXNQ MoSxS2k2OD1zLkOg{txO M4X0c|IzPDN3Nk[5
SK-MEL-28 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYe2MlIh|ryP M2PNcVczKGh? NHLLWWlFVVOR NG[zVpVIUTVyPUGg{txO MnjGNlI1OzV4Nkm=
SK-MEL-5 NV\5UmliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXq2MlIh|ryP MknuO|IhcA>? MXvEUXNQ NXr2Vnd2T0l3ME2wMlY{KM7:TR?= NEXGZ5MzOjR|NU[2PS=>
SKOV3 M13qOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PQRVYvOiEQvF2= NXH0b4s6PzJiaB?= M3HY[2ROW09? NFjlbnJIUTVyPUGg{txO NUXpcGN4OjJ2M{W2Olk>
SN12C MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln6Ok4zKM7:TR?= MlvXO|IhcA>? M1XmPGROW09? NVfSU3pUT0l3ME2yJO69VQ>? MkfzNlI1OzV4Nkm=
SNB19 NHf2RVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrmWYtRPi5{IN88US=> NGTmbI44OiCq MX;EUXNQ MnXXS2k2OD1yLk[zJO69VQ>? MkPqNlI1OzV4Nkm=
SNB75 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS2MlIh|ryP NFKybVI4OiCq M1n3ZWROW09? NUfDdGFCT0l3ME2wMlc6KM7:TR?= M3f6SVIzPDN3Nk[5
SR MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn6XI43NjJizszN MkOzO|IhcA>? M3nzUWROW09? MULHTVUxRTBwNDFOwG0> NHTK[4EzOjR|NU[2PS=>
T47D MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jDXVYvOiEQvF2= M2XDVFczKGh? NV2wO21zTE2VTx?= MnnPS2k2OD1yLkWg{txO M2HKeFIzPDN3Nk[5
TK10 NHH0dmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P0dVYvOiEQvF2= NXHaS3RPPzJiaB?= MVXEUXNQ M4LaZWdKPTB;MD62N{DPxE1? M4DPclIzPDN3Nk[5
UACC257 M4DzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7HfYw3NjJizszN MVy3NkBp NXHLOXRlTE2VTx?= MlLCS2k2OD1yLkWg{txO NH;oVoszOjR|NU[2PS=>
UACC62 NYS0d3Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInBVZE3NjJizszN NVLzTFV5PzJiaB?= M3e0VGROW09? M1v4XWdKPTB;MD60JO69VQ>? Ml3aNlI1OzV4Nkm=
UO31 NIrPbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjEUnJrPi5{IN88US=> MYi3NkBp MYLEUXNQ NWqyNJJ6T0l3ME2wMlUh|ryP M2DTb|IzPDN3Nk[5
Hep3B Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\yOFghcA>? NXrKdo1MTE2VTx?= NXn5RVhNT0l3ME2wMlY6KM7:TR?= NI[5doozOjR|OUi2Ny=>
BE(2)-C NVzrWHI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzO[nk4OiCq M3\ydmROW09? M1j3dGlEPzB;MjFOwG0> NEfDXHEzOjl|MkOxOi=>
Bel7402 NXfWVIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TRe|czKGh? NYD4V4YxTE2VTx?= NEGxXIFIUTlyPUG3JO69VQ>? MVOyN|A3OTN5Nh?=
Bel7404 Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW3NkBp MlrOSG1UVw>? M1PhV2dKQTB;MUig{txO NGDzN2ozOzB4MUO3Oi=>
BGC823 NGDMV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y3OVczKGh? NIjCXVlFVVOR MmTCS2k6OD15LkWg{txO NUS2WYs2OjNyNkGzO|Y>
MGC803 NWTlXoc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzBSGM4OiCq NFPrW2xFVVOR NIi0dINIUTlyPUGwMlgh|ryP NXLuWndbOjNyNkGzO|Y>
SGC7901 M4T0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWW3NkBp NGrE[5lFVVOR MWXHTVkxRTlwNDFOwG0> MlXJNlMxPjF|N{[=
SKHEP1 NYH0XnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nBRlczKGh? MlnWSG1UVw>? NFvMbHJIUTlyPUG3JO69VQ>? NIK1d2YzOzB4MUO3Oi=>
SMMC7721 MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17ic|czKGh? MnH0SG1UVw>? NXXT[WFUT0l7ME2yNEDPxE1? NYDlR2RCOjNyNkGzO|Y>
NUGC3 MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoewNVAh|ryP MmfrS2k:Oi57NDFOwG0> MV[yN|E3OzN|Mh?=
A2780 CisR M3PTZmtqdmG|ZTDBd5NigQ>? NFTVN|UyQCCq Ml:0TY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkS0JO69VQ>? MVGyN|I2OjZyMx?=
CAL27 sens M17tb2tqdmG|ZTDBd5NigQ>? MUixPEBp NF\YUHpKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuN|Yh|ryP NXT0XXM6OjN{NUK2NFM>
CAL27 CisR MXvLbY5ie2ViQYPzZZk> MUKxPEBp NF7ZW|dKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOlEh|ryP NELEbWQzOzJ3Mk[wNy=>
KYSE-510 CisR MWnLbY5ie2ViQYPzZZk> NWm0bm1nOThiaB?= NGrxPWFKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOVkh|ryP MVmyN|I2OjZyMx?=
KYSE-510 sens M{[4[GtqdmG|ZTDBd5NigQ>? MnvvNVghcA>? MkDRTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkeg{txO NYr1R|d3OjN{NUK2NFM>
MDA-MB-231 sens NXzxTmIzU2mwYYPlJGF{e2G7 MoTRNVghcA>? NFr2dY1KdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOlEh|ryP NVi2N|RNOjN{NUK2NFM>
MDA-MB-231 CisR M4nuU2tqdmG|ZTDBd5NigQ>? NIXNZVUyQCCq M4KyXWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1? MWOyN|I2OjZyMx?=
ES2 NIjrcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPFOFghcA>? MkLWSG1UVw>? NVzpfW97UUN3ME2xNk44KM7:TR?= MYqyN|Q6OzR2OR?=
MDA-MB-231 NFzJbpZMcW6jc3WgRZN{[Xl? NX;0dFg4OTBizszN NXvDUldbOzBibXnu M2q3V2ROW09? NHHjXIhKdmirYnn0bY9vKG:oIFjERWMz[Q>? MVKyN|Q6OzR2OR?=
MDA-MB-231 M{mwNmtqdmG|ZTDBd5NigQ>? M1voOFEh|ryP NHWy[4QzPCCq NYfFUVVCTE2VTx?= NYrIWmtyUW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=> M4PqdFI{PDl|NES5
HS68 M2P0PGN6fG:2b4jpZ{BCe3OjeR?= NV;yeHp1OTBizszN NHXXSWY4OiCq M2PQR2ROW09? NFTBUJpKSzVyPUSuOkDPxE1? MlqxNlM2PzB3NEK=
MEF NYrn[HV4S3m2b4TvfIlkKEG|c3H5 M3riW|ExKM7:TR?= M3rhW|czKGh? M172Z2ROW09? NW\xWY1oUUN3ME20MlQh|ryP MV6yN|U4ODV2Mh?=
BGC823 MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnEUXNQ MY\HTVUxRTNwMEmg{txO M4P2clI{PjBzN{C2
High5 NUflNWd6U2mwYYPlJGF{e2G7 M2LwPVI1KGh? MWrJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVO2JJdqfGhiSVO1NEBw\iByLkC5JO69VQ>? M1;wSFI{PjB{NUKz
High5 MWHLbY5ie2ViQYPzZZk> MmLINlQhcA>? NYnRcWsyUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEOSC5aYToJGlEPTBib3[gNE4yOiEQvF2= M4jhXlI{PjB{NUKz
High5 M3jLZmtqdmG|ZTDBd5NigQ>? MmrNNlQhcA>? MUHJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOzJJdqfGhiSVO1NEBw\iByLkG3JO69VQ>? M3zJTlI{PjB{NUKz
A549 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L1[GROW09? Mn7kTWM2OD1zLkC3PUDPxE1? NF7ZVVczOzZ2NEKxNC=>
HCT116 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[1XnBFVVOR MmjUTWM2OD1yLke1O{DPxE1? NUm5d5d6OjN4NESyNVA>
K562 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK5TY9oTE2VTx?= NX[xXXE5UUN3ME2wMlY1PSEQvF2= MnH4NlM3PDR{MUC=
GBC-SD NXvZWVBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfROUDPxE1? NHK4bng4OiCq MYnEUXNQ NW\aeJE4UUN3ME2xOE45KM7:TR?= MlLxNlM4ODd{NkC=
HGC27 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm1JO69VQ>? M1n6XFczKGh? MXHEUXNQ MljSTWM2OD13LkSg{txO M{SzfFI{PzB5Mk[w
HL60 NHriSGVMcW6jc3WgRZN{[Xl? M3TpTlUh|ryP NXfUflNwOjRiaB?= Ml7CSG1UVw>? M4faeWlvcGmkaYTpc44hd2ZiSFTBRy=> M2H5XlI{PzB5Mk[w
Vero MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\4[|czKGh? MWPEUXNQ MnfQTWM2OD1yLkmg{txO M17GdFI{Pzh4NEWy
NCI60 MWLDfZRwfG:6aXOgRZN{[Xl? MXO0PEBp NVvLeIJwTE2VTx?= MXvHTV0xNjV|IN88US=> NGPoZ3EzPDBzNUOyOy=>
SW620 MlPrR5l1d3SxeHnjJGF{e2G7 NYTMbZZ[PDhiaB?= NFvtNJhFVVOR NFXFd2tIUT1yLkW0JO69VQ>? NF7Gd44zPDBzNUOyOy=>
U251 NXfOO5VzS3m2b4TvfIlkKEG|c3H5 NUDUS5RWPDhiaB?= M1O3U2ROW09? MkW2S2k:OS53MzFOwG0> MUmyOFAyPTN{Nx?=
KM12 NWLEUW9RS3m2b4TvfIlkKEG|c3H5 NWj3XI14PDhiaB?= NHHYSHBFVVOR NHnGPIFIUT1zLki4JO69VQ>? M1;5flI1ODF3M{K3
Hs578T NEfYVXVEgXSxdH;4bYMhSXO|YYm= MVy0PEBp NVjvb3FyTE2VTx?= M1zsd2dKRTRwOEOg{txO MXWyOFAyPTN{Nx?=
MDA-MB-231 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLrfXk1QCCq MWTJR|UxRTBwMU[g{txO MXWyOFA6PTBzNh?=
MCF7 NV;VSJMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\iV3c1QCCq NE\MSmhIUT1yLkS1JO69VQ>? NWnYXVg4OjRzMUm1OVU>
MDA-MB-435 NV[1V5ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjG[Yg1QCCq MVrHTV0xNjh6IN88US=> Mk\YNlQyOTl3NUW=
AsPC1 NIH0T45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLLenJROzBizszN NWXZXJFoPDhiaB?= MkfsSG1UVw>? M{PM[2lEPTB;Mz62OkDPxE1? MmfyNlQyQDV|N{i=
Jurkat E6.1 M1rqPWtqdmG|ZTDBd5NigQ>? MUGyJIg> MmPPSG1UVw>? Mk\1TY5pcWKrdHnvckBw\iCKRFHDOEB4cXSqIFnDOVAhd2ZiMD6wOEDPxE1? Mo\ENlQzPjF6NkK=
KG1 M3TQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHNS5Y{PDhiaB?= NXjiZoZXUUN3ME2xMlE2KM7:TR?= NGHCVGYzPDV{NUCwNy=>
HEL M3TabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIThSpI1QCCq NHTLbYhFVVOR NIL1V5ZKSzVyPUCuOFkh|ryP MoHwNlQ3QTRyNUW=
HSC3 M1vaNmN6fG:2b4jpZ{BCe3OjeR?= NU\s[llbOTJiaB?= MVfEUXNQ NFvIV2pKSzVyPUCuO|Eh|ryP MorMNlQ4PjZ3NkC=
HT-29 MXHDfZRwfG:6aXOgRZN{[Xl? MojmNVIhcA>? MnmySG1UVw>? NXTQVVZbUUN3ME2wMlczKM7:TR?= M3W1RlI1PzZ4NU[w
KB MoLVR5l1d3SxeHnjJGF{e2G7 MXqxNkBp NWnPWmcyTE2VTx?= Mn;yTWM2OD1yLke1JO69VQ>? MWiyOFc3PjV4MB?=
H460 NEDmTFhEgXSxdH;4bYMhSXO|YYm= NUm1fFN2OTJiaB?= NYD3[5R5TE2VTx?= NYLEbJgyUUN3ME2wMlgzKM7:TR?= MoOzNlQ4PjZ3NkC=
MONE1 NYjtNWdNS3m2b4TvfIlkKEG|c3H5 MnO1NVIhcA>? NHuw[IJFVVOR NFfwNIdKSzVyPUGuNVgh|ryP NWDubppwOjR5Nk[1OlA>
MKN45 M3z3V2N6fG:2b4jpZ{BCe3OjeR?= NEP3SogyOiCq M3TLNmROW09? NWeycmI2UUN3ME2xMlI2KM7:TR?= MoL3NlQ4PjZ3NkC=
TSGH M{\3dmN6fG:2b4jpZ{BCe3OjeR?= M2\FVVEzKGh? Mk\vSG1UVw>? NVrsWVNIUUN3ME2yMlA6KM7:TR?= Ml[5NlQ4PjZ3NkC=
HL60 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2CxRlczKGh? M1SyXWROW09? NVLIbI9nT0l3ME2wMlk{KM7:TR?= MUmyOFkxODVyMB?=
HEK293 M{TkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLuO|IhcA>? MXPEUXNQ M136e2dKPTB;MUOg{txO MV2yOFkxODVyMB?=
Jurkat NIPWSWtEgXSxdH;4bYMhSXO|YYm= NIXuVVUyODBizszN NGHk[I44OiCq M4nTUmdKPTB;MD65JO69VQ>? MkLrNlQ6ODB5NEO=
GM15850 MXvLbY5ie2ViQYPzZZk> Mn22Nk42KM7:TR?= MUm5OkBp NVvM[JZOTE2VTx?= MXvkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgNVQh[WOndInsZZRqd25ib3[gSnhPKGenbnW= M{jMXFE3QTJzM{[3
GM15850 NUKyU|c6U2mwYYPlJGF{e2G7 NVPtTFFrOi53IN88US=> MnnXPVYhcA>? M3Hl[WROW09? Mk\Q[I9meyCwb4SgbY5pcWKrdDDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW= NH\DO3IyPjl{MUO2Oy=>
GM15850 M2\oVmtqdmG|ZTDBd5NigQ>? MmnoNk42KM7:TR?= M3\hWFk3KGh? MkX6SG1UVw>? MV;kc4V{KG6xdDDpcohq[mm2IFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVIh[WOndInsZZRqd25ib3[gSnhPKGenbnW= Mk\GNVY6OjF|Nke=
GM15850 NH\JVI9McW6jc3WgRZN{[Xl? NE\iTIkzNjVizszN MoDDPVYhcA>? MXjEUXNQ NEL3Nnhld2W|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm|dH;u[UBJOyCueYPpcoUhQSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=> NIi4OoQyPjl{MUO2Oy=>
GM15850 M1ThSWtqdmG|ZTDBd5NigQ>? MV:yMlUh|ryP NG\TSXQ6PiCq MmnVSG1UVw>? NU\2cHBJ\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDhiYXPleJlt[XSrb36gc4YhTliQIHflcoU> M4XUTVE3QTJzM{[3
GM15850 NFKxZpBMcW6jc3WgRZN{[Xl? M4ewcFIvPSEQvF2= NVfIb2FnQTZiaB?= MUXEUXNQ NHLTdGZld2W|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm|dH;u[UBJPCCueYPpcoUhOTZiYXPleJlt[XSrb36gc4YhTliQIHflcoU> MkWxNVY6OjF|Nke=
GM15850 NYnGXYxFTnWwY4Tpc44hSXO|YYm= MYW1JO69VQ>? NUPnTWtIOTJiaB?= MXnEUXNQ NEXnUHRp[XNibn:g[YZn\WO2IH;uJGZZViCvUl7BJIV5eHKnc4Ppc44> M1;rcFE3QTJzM{[3
U937 NE\xVlZMcW6jc3WgRZN{[Xl? NU\jWHZmPSEQvF2= MlHqNlQhcA>? M2DrVGROW09? NX;C[pNbcGG|IH7vJIVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u M{GzS|E4PDR5N{Ww
U937 MY\LbY5ie2ViQYPzZZk> NF\pfHQyKM7:TR?= MkW2NlQhcA>? Mn2zSG1UVw>? MoHDbIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w NWHJSI55OTd2NEe3OVA>
PANC1 NU\nd5ZoTnWwY4Tpc44hSXO|YYm= MV6xJO69VQ>? MXyyOEBp NF3OPWhld2W|IH7veEBqdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW|c3nvci=> NYLnS|dVOTd3OEi3OFQ>
PANC1 NVr4ZoI4TnWwY4Tpc44hSXO|YYm= NH\GWlQyKM7:TR?= Mm\DOFghKGh? M3v6UYRw\XNibn;0JIlv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO|aX;u M3fxeFE4PTh6N{S0
Caco-2 MWTGeY5kfGmxbjDBd5NigQ>? NEH4eGw2KM7:TR?= NE\lcoszPCCq Mke5SG1UVw>? M{\LSoRw\XNibn;0JIlv\HWlZTDQNlFYSUZzIHflcoUh\XiycnXzd4lwdg>? M33iXlIxOTR|OESw
SCC4 MYHGeY5kfGmxbjDBd5NigQ>? MU[xJO69VQ>? MlLRNVAhdWmw MV\EUXNQ M4PCb4hieyCwbzDh[49vcXO2IHHjeIl3cXS7IHH0JHZFWiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhS1mSMkSg[4Vv\SCneIDy[ZN{cW:w NWfkT5YzOjB2NUKyNlU>
A549 NW\TRYs3TnWwY4Tpc44hSXO|YYm= NYDtdlF[PSEQvF2= NH7BbJA{KGh? M12yUGROW09? Mke2[I9meyCwb4SgbY5lfWOnIHH1eI9xcGGpeTDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=> MnnmNlA5PTV{MEi=
HCT116 MWfLbY5ie2ViQYPzZZk> MlHZNE4{KM7:TR?= NFLEUo4{OCCq NY\kO2pZTE2VTx?= M3i0NYRw\XNibn;0JIlvcGmkaYSgTGRCSzFiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGirc4TvcoUhUDONOTDhZ4V1gWyjdHnvci=> Moj1NlExQDB4NEe=
HepG2 MkDlSpVv[3Srb36gRZN{[Xl? NFLG[GoyOCEQvF2= MoTRNlQhcA>? M2TRb2ROW09? MnLQ[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BpgXCncnHj[ZR6dGG2aX;uJI9nKHB3Mx?= MUOyNVU1QDV6Mh?=
GM11272 M3\YcWZ2dmO2aX;uJGF{e2G7 NHL5XFYxNjFizszN MXO3NkBp M2TjUWROW09? M2fJXYRw\XNibn;0JJJm[WO2aY\heIUhVWWFcEKgcZV1[W62IHX4dJJme3Orb36= NWPXWG4yOjF6NEC3NVY>
MDA-MB-231 NXLC[4o2U2mwYYPlJGF{e2G7 MYCxNEDPxE1? NXz3ZWlvPSCvaX6= MmraSG1UVw>? MYLkc4V{KG6xdDDpcohq[mm2IFjERWMz[Q>? MV[yN|Q6OzR2OR?=
MDA-MB-231 MYXLbY5ie2ViQYPzZZk> NYT3[odCOSEQvF2= MkLFNlQhcA>? M{LmSmROW09? NEe0cZdld2W|IH7veEBqdmirYnn0JGhFSUN4IHHzd4V{e2WmIHHzJIFk\XS7bHH0bY9vKGyndnXsd{Bw\iC2dXL1cIlv MYWyN|Q6OzR2OR?=
K562 NUDoPXJ4U2mwYYPlJGF{e2G7 MVrkc4V{KG6xdDDpcohq[mm2IFjERWM> M3vCS|I{PTlzMUGx
Jurkat M2fLdmN6fG:2b4jpZ{BCe3OjeR?= MXSyNEDPxE1? MYG3NkBp NITLcoZFVVOR NEjIc5pvdyCleYTveI95cWOrdImgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44> MVSyOFMxPDN2OB?=
HCT116 NUnZ[pdsSXCxcITvd4l{KEG|c3H5 NFLUXI4{KM7:TR?= MVuyOEBp Mlm0SG1UVw>? NYr3b4Rp\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMheHKxdHXpckBt\X[nbB?= MX:yOFc3PjV4MB?=
KASUMI-1 NWrs[HZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G3WGlEPTB;OUmuNVchdk1? MlX2V2FPT0WU
KARPAS-45 M3;PS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF5Mz64PUBvVQ>? NFPYUmZUSU6JRWK=
BHT-101 M1H0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTJTWM2OD1{NESuNVghdk1? NWTl[FJ3W0GQR1XS
H9 M2W5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ3NT6wOEBvVQ>? NWr4TXkyW0GQR1XS
PA-1 NHK5OHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLQXWVKSzVyPUK4Ok4zPiCwTR?= MnfzV2FPT0WU
NEC8 M2m4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ6OT6zPEBvVQ>? NYX5PIs{W0GQR1XS
MHH-PREB-1 M4jjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfnS4NKSzVyPUK5OE42OyCwTR?= M1PSVnNCVkeHUh?=
NB7 M2WzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN2NT63OEBvVQ>? M3HjfHNCVkeHUh?=
A3-KAW NFPubWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfEN45JUUN3ME20NFAvPTlibl2= M{PIWXNCVkeHUh?=
NB69 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m5fWlEPTB;NEGxMlcyKG6P M1;NPXNCVkeHUh?=
EoL-1-cell M{Ph[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ZTWM2OD12NUSyOUBvVQ>? NHizVZdUSU6JRWK=
CHP-212 NHTNdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP5bodrUUN3ME20OVcvPTNibl2= MVzTRW5ITVJ?
C2BBe1 NXr3[3dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGeydYRKSzVyPUS3Nk4yQSCwTR?= M4LoV3NCVkeHUh?=
697 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTR5Mz60NUBvVQ>? MXLTRW5ITVJ?
BCPAP NXey[4xKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVyMT60NkBvVQ>? NHPKSWFUSU6JRWK=
L-363 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzvNHdKSzVyPUWwN{4yKG6P NGOwWnpUSU6JRWK=
ES8 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKxTWM2OD13MkOuOVMhdk1? NH62ZWxUSU6JRWK=
BE-13 M4i4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTV{Nj65OkBvVQ>? MYXTRW5ITVJ?
CTB-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTV|Nz65NkBvVQ>? MnXXV2FPT0WU
HD-MY-Z M172Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nsbmlEPTB;NUO4MlE{KG6P NUm4XGZzW0GQR1XS
NKM-1 NYrIeJdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTsSXlKSzVyPUW0OE4zPyCwTR?= MV3TRW5ITVJ?
NCI-H720 NILmTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTV4MD6xPEBvVQ>? NH3ETVJUSU6JRWK=
KY821 Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\5fGlEPTB;NU[zMlI2KG6P MUHTRW5ITVJ?
OVCAR-5 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnZTWM2OD13N{[uNVEhdk1? MUPTRW5ITVJ?
CTV-1 NGDlR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOxTWM2OD13OEGuOVYhdk1? NVzsdlZzW0GQR1XS
P12-ICHIKAWA MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF75c45KSzVyPUW5Ok42OSCwTR?= M3rHU3NCVkeHUh?=
DB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHNfoxKSzVyPUW5PE42PyCwTR?= M3\KU3NCVkeHUh?=
CHL-1 NVzWRXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrZNlhUUUN3ME22OFIvODhibl2= MoPEV2FPT0WU
A4-Fuk M3PPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LXXWlEPTB;NkS0MlkyKG6P NV7kR4N6W0GQR1XS
MV-4-11 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnZTWM2OD14NUmuNUBvVQ>? M2K3fnNCVkeHUh?=
RPMI-8226 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[2TWM2OD14N{iuNVghdk1? NX;hbmJLW0GQR1XS
NB14 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorPTWM2OD14OU[uPVUhdk1? M1u3PXNCVkeHUh?=
DOHH-2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonGTWM2OD15ME[uOlghdk1? NGDqUJNUSU6JRWK=
D-423MG MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID3fpZKSzVyPUewOk45QSCwTR?= MXfTRW5ITVJ?
D-283MED MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjuXWhKSzVyPUexOE4yPCCwTR?= NWXER4F{W0GQR1XS
ES1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnjcWhKSzVyPUeyOE41KG6P M3\STnNCVkeHUh?=
GOTO NIO0VGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj5Tm9KSzVyPUeyPU4yOiCwTR?= MVrTRW5ITVJ?
NCI-H209 NV;pd|JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\1epVKSzVyPUeyPU46KG6P MX;TRW5ITVJ?
MOLT-13 M{CwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjGSndKSzVyPUezPE46QCCwTR?= MmTKV2FPT0WU
ATN-1 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzxU|FKSzVyPUe0NE4zQCCwTR?= M1HpUHNCVkeHUh?=
DU-4475 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnZTWM2OD15NUGuPVEhdk1? NVHiUHBrW0GQR1XS
NB10 MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi5e29KSzVyPUe1NU46OiCwTR?= NXrJSZBiW0GQR1XS
KG-1 M3Xtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7CVXFKSzVyPUe3OU41PSCwTR?= NVPrc4tXW0GQR1XS
MOLT-4 NXTOSotqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P6VWlEPTB;N{i3MlQ3KG6P M3jV[HNCVkeHUh?=
TE-1 NVS3ZmlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe0NItKSzVyPUe5NU4yKG6P NHHhbZpUSU6JRWK=
SBC-1 NIfSSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjBN4tuUUN3ME23PVMvQDRibl2= MYPTRW5ITVJ?
HEL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRThyNj6wPEBvVQ>? NUO2PG5DW0GQR1XS
SK-MEL-2 M2fZcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPOTWM2OD16MEmuOFQhdk1? NXHCSldMW0GQR1XS
KU812 NYH3d3BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\6[mNJUUN3ME24NVMvOSCwTR?= NIe1bVhUSU6JRWK=
RPMI-8866 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRThzMz62O{BvVQ>? MYrTRW5ITVJ?
ALL-PO NVXMOWhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;TTllKSzVyPUixOE43PiCwTR?= Mk\BV2FPT0WU
LU-139 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DsWmlEPTB;OEKyMlg3KG6P NIHqR3lUSU6JRWK=
RS4-11 NYPtNodQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLtTWM2OD16M{KuOFUhdk1? NW[4XFlyW0GQR1XS
EW-18 NGXT[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXiTWM2OD16M{KuPVYhdk1? MlrQV2FPT0WU
P30-OHK NVXsW5NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknmTWM2OD16M{WuO{BvVQ>? NG[wO4xUSU6JRWK=
D-566MG M4G4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj4TWM2OD16M{iuOlIhdk1? MlTaV2FPT0WU
HSC-4 NED4S2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzkTWM2OD16NE[uOVEhdk1? NYDaTWpmW0GQR1XS
QIMR-WIL M4fKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LRU2lEPTB;OE[yMlA{KG6P MYPTRW5ITVJ?
SW954 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIradVFKSzVyPUi2N{4yPiCwTR?= MV\TRW5ITVJ?
HGC-27 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTh5Mj6zOEBvVQ>? MWTTRW5ITVJ?
HH NF;3epZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXT[FhKSzVyPUi5OE4yOiCwTR?= MXzTRW5ITVJ?
KE-37 NEOxd|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTh7ND62NkBvVQ>? MUTTRW5ITVJ?
SK-N-DZ NX\mPFE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2npc2lEPTB;OUCwMlQ{KG6P M165WnNCVkeHUh?=
J-RT3-T3-5 NFPiVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTlzMD60PUBvVQ>? NH\GelJUSU6JRWK=
A427 NHnlVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTl{MD64OEBvVQ>? MkfUV2FPT0WU
ECC10 NFuyN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK0VJFKSzVyPUm0OU45PyCwTR?= MVLTRW5ITVJ?
EW-1 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPiTWM2OD17NEeuNlYhdk1? MXLTRW5ITVJ?
MIA-PaCa-2 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jrcGlEPTB;OUS5MlEzKG6P MoLyV2FPT0WU
HCC2218 MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;rTWM2OD17NUiuOFghdk1? Mmj6V2FPT0WU
HAL-01 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTKOphXUUN3ME25OlgvODRibl2= MXPTRW5ITVJ?
RD NVO2[3djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml31TWM2OD17N{SuOFUhdk1? NXfZUHR{W0GQR1XS
SK-N-AS NEnjOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTl6OD6xJI5O M1jZSHNCVkeHUh?=
ML-2 NUDrNpVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH22NmlKSzVyPUGuNFA1ODdizszN MoO4V2FPT0WU
MEL-HO MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG0TWM2OD1zLkCwOVgzKM7:TR?= M3nZOXNCVkeHUh?=
MS-1 NX[xfnRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPpTWM2OD1zLkCwOlE4KM7:TR?= MmOwV2FPT0WU
NCI-SNU-1 M{jRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH1blRtUUN3ME2xMlAzOzNzIN88US=> MkTKV2FPT0WU
8505C M2jDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;tSWlEPTB;MT6wNlM{OSEQvF2= NGjkeHVUSU6JRWK=
MN-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWyRXB4UUN3ME2xMlAzPjhizszN NWHuTlZ6W0GQR1XS
SAS NV3kWpM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTpZ4NKSzVyPUGuNFQxQDFizszN MUTTRW5ITVJ?
EFM-19 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13yemlEPTB;MT6wOFg4QSEQvF2= M121XnNCVkeHUh?=
Ca9-22 M1flfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3wV5pKSzVyPUGuNFUyODdizszN NUm3UZJnW0GQR1XS
NBsusSR NV3DN5pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7CUXlKSzVyPUGuNFUyPjZizszN Mln2V2FPT0WU
NB13 NIrFdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTzTWM2OD1zLkC1OVAyKM7:TR?= MX;TRW5ITVJ?
SF295 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH5TWM2OD1zLkC2OlI1KM7:TR?= NFHrWHBUSU6JRWK=
U-2-OS MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjucIhKSzVyPUGuNFc6OTFizszN M37N[XNCVkeHUh?=
NCI-H526 M3jvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwMEiyPVEh|ryP M1X2NnNCVkeHUh?=
KMOE-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm0TWM2OD1zLkC5OFIzKM7:TR?= NGm2TZFUSU6JRWK=
RCM-1 NGf4flBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu2ZY5KSzVyPUGuNVIyODJizszN NY[3U3lyW0GQR1XS
MC116 M3eyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;aWYVKSzVyPUGuNVM3OjFizszN NIO3V2VUSU6JRWK=
NCI-H1092 NXLRTXZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHiS5Y1UUN3ME2xMlE2PDB4IN88US=> NVjIcm1lW0GQR1XS
EW-3 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzydHFKSzVyPUGuNVczOTJizszN NFLXeVVUSU6JRWK=
HCT-116 M2Dibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDoZWZDUUN3ME2xMlE4PzVizszN Mme5V2FPT0WU
MC-IXC Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3ITWM2OD1zLkG3PFgyKM7:TR?= NIrsemNUSU6JRWK=
LB1047-RCC M2fVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwMUizNVIh|ryP NXX0UGh3W0GQR1XS
VM-CUB-1 M1;qUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHXTWM2OD1zLkG5NVA5KM7:TR?= M2PLXnNCVkeHUh?=
NB5 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXKTWM2OD1zLkG5PFU3KM7:TR?= Mni5V2FPT0WU
SKG-IIIa NI[5N41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHXTWM2OD1zLkKzOFY1KM7:TR?= NH7udIlUSU6JRWK=
HO-1-N-1 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W2[mlEPTB;MT6yN|g{PSEQvF2= M3rxc3NCVkeHUh?=
EFO-27 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwMkWwOFMh|ryP MmLFV2FPT0WU
MHH-NB-11 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwMkizNlkh|ryP NGHuXpFUSU6JRWK=
SW620 NXPOXnFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy3[GJVUUN3ME2xMlI6ODF6IN88US=> NEPUdmJUSU6JRWK=
MOLT-16 NI\zUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LWO2lEPTB;MT6yPVc6PyEQvF2= MoXDV2FPT0WU
NTERA-S-cl-D1 M3LZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwM{G3OlEh|ryP NVHFbHpMW0GQR1XS
VA-ES-BJ NIj4VFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLhTWM2OD1zLkOyOFc4KM7:TR?= NH62UoNUSU6JRWK=
HCC1419 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\LTWM2OD1zLkO0NFI4KM7:TR?= MVPTRW5ITVJ?
NCI-H69 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j5UGlEPTB;MT6zOFEyOiEQvF2= NUXweZdsW0GQR1XS
DEL NUjNUVB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjmTWM2OD1zLkO1NVYzKM7:TR?= NX;SeotsW0GQR1XS
LXF-289 MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwM{WyOEDPxE1? MlvkV2FPT0WU
EW-11 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\PU5N1UUN3ME2xMlM3ODJ4IN88US=> NVr0OWdnW0GQR1XS
KP-4 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFwM{ewPFUh|ryP NX7SZmlrW0GQR1XS
NOS-1 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rGNmlEPTB;MT60NVE6PCEQvF2= MX;TRW5ITVJ?
SK-NEP-1 MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O1XWlEPTB;MT60NVY6OyEQvF2= Ml;tV2FPT0WU
LAMA-84 NYjO[IpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jSVGlEPTB;MT60N|k1PSEQvF2= Ml7EV2FPT0WU
ES5 Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzkTWM2OD1zLkS0N{DPxE1? MVvTRW5ITVJ?
HuO9 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXlNFdKSzVyPUGuOFU{PjJizszN MVrTRW5ITVJ?
COLO-684 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe5WFVoUUN3ME2xMlQ3OTF6IN88US=> NYCyWGFMW0GQR1XS
EW-24 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwNE[1N|Eh|ryP NGGxfFVUSU6JRWK=
BV-173 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvVTWM2OD1zLkS3NlkyKM7:TR?= Mm[4V2FPT0WU
NCI-H1770 M{XZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjaNXZKSzVyPUGuOFg2OzZizszN Mmj3V2FPT0WU
HuP-T4 NEP5TnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO3OY1KSzVyPUGuOFk{KM7:TR?= M37HbnNCVkeHUh?=
TYK-nu NUTrWod3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwNEm4OVEh|ryP MX3TRW5ITVJ?
YH-13 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFixU3dKSzVyPUGuOFk5QTRizszN NX\Qd|hGW0GQR1XS
H4 M2PGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTGOnFZUUN3ME2xMlUxQTF{IN88US=> NIDsWFVUSU6JRWK=
OVCAR-8 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TxWWlEPTB;MT61OFQ4PyEQvF2= NV7QSoM4W0GQR1XS
NCI-H23 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;nZWlEPTB;MT61OFY1PSEQvF2= NWLONHgxW0GQR1XS
ES7 M2TEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwNUS3O|Mh|ryP M4rQS3NCVkeHUh?=
COR-L88 M1zLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3TOphKSzVyPUGuOVY1OjRizszN NY\3SpdJW0GQR1XS
TI-73 NVqy[YxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHOTHNKSzVyPUGuOVkxPiEQvF2= NUfSSYdoW0GQR1XS
RT-112 M2\SZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHJT4RKSzVyPUGuOVkzQDRizszN NX7ieIpvW0GQR1XS
HuO-3N1 M3PqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7iTWM2OD1zLkW5N|g2KM7:TR?= MV\TRW5ITVJ?
HC-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS3TWM2OD1zLkW5PFY3KM7:TR?= M3LmVXNCVkeHUh?=
HT55 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\yUnBKSzVyPUGuOlUyOzFizszN MULTRW5ITVJ?
IA-LM NH3GPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwNkmyO|gh|ryP NXOyNFVOW0GQR1XS
EM-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwN{CwNVQh|ryP NYWzc2hZW0GQR1XS
MHH-ES-1 M3y4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPmTWM2OD1zLkewOFM2KM7:TR?= MniwV2FPT0WU
CAL-27 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T5PWlEPTB;MT63NFYzOSEQvF2= Moq3V2FPT0WU
COLO-800 NIXqd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTVZZVVUUN3ME2xMlcyOTd7IN88US=> NV7meVdEW0GQR1XS
HCE-T NIjS[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTqTWM2OD1zLkexOUDPxE1? MkDOV2FPT0WU
CAMA-1 MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3IWplKUUN3ME2xMlcyQTdzIN88US=> M4PaPHNCVkeHUh?=
LOXIMVI M17W[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFwN{KxNUDPxE1? NXPkOIZwW0GQR1XS
NH-12 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwN{K2PVEh|ryP MVjTRW5ITVJ?
TCCSUP MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwN{K4Nlkh|ryP NF3OO4lUSU6JRWK=
MDA-MB-361 M{PFT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwN{OxOVch|ryP MnTjV2FPT0WU
EW-16 Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfrTWM2OD1zLke0NVA4KM7:TR?= MYrTRW5ITVJ?
SNU-423 NEj2PVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:wRndLUUN3ME2xMlc2QDJ5IN88US=> M1LuS3NCVkeHUh?=
Daoy MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwN{[zNVkh|ryP MUjTRW5ITVJ?
ES4 MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi0dFJKSzVyPUGuO|g4PDFizszN MofEV2FPT0WU
PFSK-1 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW2TWM2OD1zLkiwN|ch|ryP NYnCPJVVW0GQR1XS
ES3 NX7Zc2I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf2dGhtUUN3ME2xMlgzPjhzIN88US=> NXvkXpNpW0GQR1XS
ONS-76 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\nT452UUN3ME2xMlgzQDl5IN88US=> NH32R21USU6JRWK=
JVM-3 NIe4fpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\hTWM2OD1zLki1OFUyKM7:TR?= MXTTRW5ITVJ?
OS-RC-2 M4XUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;0NYlKSzVyPUGuPFcyPTFizszN MWrTRW5ITVJ?
COLO-320-HSR MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn73TWM2OD1zLki4NVk4KM7:TR?= NFPFVHNUSU6JRWK=
HN NEfTZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\hNHdrUUN3ME2xMlg5PzJ3IN88US=> Mli3V2FPT0WU
HT NFvnNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwOEi5OFch|ryP MXLTRW5ITVJ?
LoVo M{\ldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXFTWM2OD1zLki5PFEh|ryP MkLIV2FPT0WU
CGTH-W-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;uWmlEPTB;MT64PVk1PiEQvF2= MVzTRW5ITVJ?
NB6 NXXBUlBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLlTWM2OD1zLkmxNlk5KM7:TR?= Ml;hV2FPT0WU
EW-22 NW\CZYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPITWM2OD1zLkmyPFg4KM7:TR?= NUfwTVdPW0GQR1XS
ES6 NFTjTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwOUO2N|Eh|ryP MlfsV2FPT0WU
SCC-15 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\lfGlEPTB;MT65N|gyQSEQvF2= M{jTdnNCVkeHUh?=
HL-60 NIPzRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi5XFZFUUN3ME2xMlk{QTB{IN88US=> NWnzWlZmW0GQR1XS
human HOP-92 NYfPc4s1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFwOUSwOlUh|ryP NUTVUHVDW0GQR1XS
SW626 NHjZS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jabmlEPTB;MT65OFg6QSEQvF2= MmPUV2FPT0WU
HEC-1 NWT6[WZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzYOohKSzVyPUGuPVU{PiEQvF2= MljUV2FPT0WU
LB2241-RCC NHrmR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfKdohKSzVyPUGuPVgzOzFizszN MnvZV2FPT0WU
Ramos-2G6-4C10 NWHlZZhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwOUm0PVMh|ryP NWn1S4VxW0GQR1XS
A101D NFnsb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon4TWM2OD1{LkKwN|A{KM7:TR?= NFjCNGpUSU6JRWK=
NCI-H446 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\3TWM2OD1{LkC0OVk6KM7:TR?= NFzrbnFUSU6JRWK=
SBC-5 NXT4NZdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnCbYVKSzVyPUKuNFYyPDdizszN NF3lZXpUSU6JRWK=
HOS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;SW5YxUUN3ME2yMlA4PjV|IN88US=> NFvXV5NUSU6JRWK=
K5 M{XNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjaTWM2OD1{LkC3PFEyKM7:TR?= NGXOdXFUSU6JRWK=
HLE NETNXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ZSmlEPTB;Mj6wPFUzQSEQvF2= MYjTRW5ITVJ?
HSC-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP2b4FKSzVyPUKuNVI5QThizszN MmrLV2FPT0WU
LCLC-97TM1 NIfkSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHkTWM2OD1{LkG0OVg{KM7:TR?= MUfTRW5ITVJ?
DMS-273 NXHM[VlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7yTWM2OD1{LkG0PFM4KM7:TR?= MVvTRW5ITVJ?
TE-8 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXVc2VKSzVyPUKuNVU4PjVizszN Ml73V2FPT0WU
DSH1 M4LQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJwMU[zPVgh|ryP M{XzNHNCVkeHUh?=
CAL-51 NWjlR4ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOxSVdKSzVyPUKuNVY3QTlizszN M3P6e3NCVkeHUh?=
IST-SL1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe1TZRSUUN3ME2yMlE3QDR2IN88US=> NHnUbmlUSU6JRWK=
GCT NHXKSodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H2cWlEPTB;Mj6xO|c4KM7:TR?= MoTUV2FPT0WU
SW948 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjlO3NKSzVyPUKuNVg1PTZizszN NYHLd3gyW0GQR1XS
NOMO-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJwMUmzNVch|ryP MYXTRW5ITVJ?
C8166 M{TsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3Hc4pTUUN3ME2yMlIyOzN2IN88US=> MU\TRW5ITVJ?
OC-314 M1L0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT6TYRKSzVyPUKuNlMzPTlizszN NHq3UmVUSU6JRWK=
CAL-39 NGnsXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMkO2NlYh|ryP MmezV2FPT0WU
MDA-MB-453 Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwMkSyO|Uh|ryP MV;TRW5ITVJ?
A673 M4P4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfSXXFyUUN3ME2yMlI2QDZ{IN88US=> MU\TRW5ITVJ?
HTC-C3 M1zVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\TRZpKSzVyPUKuNlY5PSEQvF2= M2LMNHNCVkeHUh?=
NCI-H1666 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDrWohKSzVyPUKuNlgyOTFizszN M3TxSHNCVkeHUh?=
PSN1 NGrwN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH5RmVqUUN3ME2yMlI5QTF|IN88US=> NUX3SmJHW0GQR1XS
GI-1 MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vjOGlEPTB;Mj6zNFU1OyEQvF2= MX\TRW5ITVJ?
HuH-7 NXzwWoI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vTTGlEPTB;Mj6zNFY{PyEQvF2= NYD3NHBWW0GQR1XS
JAR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[3[mZKSzVyPUKuN|E6QDdizszN MYDTRW5ITVJ?
5637 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJwM{KxNlkh|ryP NX7TcYE1W0GQR1XS
GB-1 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nrT2lEPTB;Mj6zNlM{PSEQvF2= M1nCRXNCVkeHUh?=
KP-N-YS NYmyWHYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu4TWM2OD1{LkOyOlE2KM7:TR?= MYjTRW5ITVJ?
OAW-42 M1Xxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJwM{O0NVYh|ryP NV\lUYszW0GQR1XS
8-MG-BA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG5WXBKSzVyPUKuN|M6ODZizszN Ml3YV2FPT0WU
RH-18 NVrtRZpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJwM{WwNlIh|ryP M2HkPXNCVkeHUh?=
NCI-H1155 NX;GXHJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwM{[3NlUh|ryP NFnCWGtUSU6JRWK=
NB17 NHn0V|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlGxTWM2OD1{LkO4NlQ{KM7:TR?= M3LpcHNCVkeHUh?=
NCI-H1437 NXv4RVg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjRWWtqUUN3ME2yMlQyQDd|IN88US=> NWjMOIc{W0GQR1XS
SN12C MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHw[lRKSzVyPUKuOFMzOTRizszN NITKN|dUSU6JRWK=
HSC-3 NV\ofpNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJwNES1NFkh|ryP MX\TRW5ITVJ?
GAMG Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;yRYpjUUN3ME2yMlQ1PTZzIN88US=> MkfvV2FPT0WU
HT-1080 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLkeItNUUN3ME2yMlQ1QDZ2IN88US=> Mlr1V2FPT0WU
A549 NEP3XWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJwNES4PVMh|ryP NFrZXItUSU6JRWK=
KNS-62 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJwNEWwOlEh|ryP NYL2dFRIW0GQR1XS
YKG-1 M3vIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;n[4wxUUN3ME2yMlQ2PDN5IN88US=> NFLSW2NUSU6JRWK=
LU-134-A NGLF[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwNEewNFgh|ryP NH7u[WZUSU6JRWK=
FADU MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzkTWM2OD1{LkS3NVYzKM7:TR?= MkDjV2FPT0WU
TGBC11TKB MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXsTWM2OD1{LkS3NVc4KM7:TR?= M2PzZXNCVkeHUh?=
HT-3 NUH2Vok3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf3T5hKSzVyPUKuOFk2OzVizszN NGjCVJdUSU6JRWK=
NCI-H2170 NFvYcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCzTWM2OD1{LkWwOVQ6KM7:TR?= NGjad3ZUSU6JRWK=
Mo-T NFrLdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PKU2lEPTB;Mj61NFkzPyEQvF2= MWHTRW5ITVJ?
CCRF-CEM MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJwNUOwOFMh|ryP NVTOZXZNW0GQR1XS
KU-19-19 NHnMZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G2SmlEPTB;Mj61N|UyOyEQvF2= MWXTRW5ITVJ?
NCI-H1048 M{\uR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHxUoJxUUN3ME2yMlU2ODJ3IN88US=> M1HjUHNCVkeHUh?=
KOSC-2 NFjyc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwNU[wO|Yh|ryP M3nsN3NCVkeHUh?=
A431 NVzp[FBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJwNU[zN|Uh|ryP NHr4cGFUSU6JRWK=
COR-L23 NIr2V25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnsbJZKSzVyPUKuOVg2PjZizszN MVnTRW5ITVJ?
MKN28 Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;yO2lEPTB;Mj61PVA{PyEQvF2= MknGV2FPT0WU
22RV1 NUPaOnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LuOWlEPTB;Mj61PVI4PCEQvF2= MknrV2FPT0WU
ABC-1 NWPIS4xZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwNkC0OkDPxE1? MVPTRW5ITVJ?
NCI-H2126 NHXMVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJwNkC5PFQh|ryP NUTKfnN5W0GQR1XS
DoTc2-4510 NIXIPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq0dlRKSzVyPUKuOlIyQDVizszN NXvBVoFNW0GQR1XS
SCC-4 NYjXPVc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO2Z4ZkUUN3ME2yMlY{ODF{IN88US=> MWPTRW5ITVJ?
NCI-H661 M4S1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwNkSwPFUh|ryP MmXzV2FPT0WU
RPMI-2650 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq3TWM2OD1{Lk[0NVQ{KM7:TR?= M13r[nNCVkeHUh?=
NCI-H510A Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETKeoRKSzVyPUKuOlQ1OjZizszN NFrVZWtUSU6JRWK=
BPH-1 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPNTWM2OD1{Lk[1PFUh|ryP NX\iOXlNW0GQR1XS
M14 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDRPVltUUN3ME2yMlY3QTl|IN88US=> MnHmV2FPT0WU
G-402 Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\PN2tKSzVyPUKuO|A1PTFizszN Mo\NV2FPT0WU
AsPC-1 NUXidJd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnFOIdSUUN3ME2yMlcyOTdizszN M4PHOXNCVkeHUh?=
NB12 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJwN{G3NUDPxE1? MVnTRW5ITVJ?
SK-HEP-1 NWrCb5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJwN{SzPVEh|ryP NXnDeYx7W0GQR1XS
U-266 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jXWmlEPTB;Mj63O|EzOSEQvF2= Ml\CV2FPT0WU
AM-38 NHTNNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\PXVF5UUN3ME2yMlc4OzV3IN88US=> NFT5eINUSU6JRWK=
PC-14 NF\EWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJwOEC1NUDPxE1? MoLMV2FPT0WU
EGI-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjTTWM2OD1{LkixO|Q{KM7:TR?= MXXTRW5ITVJ?
LS-411N NWG5NYw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJwOEKzN{DPxE1? Ml74V2FPT0WU
BFTC-905 NH3vbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJwOEW1NlMh|ryP MkDCV2FPT0WU
CaR-1 NFPrV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfF[mtKSzVyPUKuPFYh|ryP MUTTRW5ITVJ?
NCI-H292 M4C2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJwOE[1PVYh|ryP MUHTRW5ITVJ?
8305C MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJwOE[2OFUh|ryP MmThV2FPT0WU
SNU-449 NV;wZ5V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTUV2lKSzVyPUKuPFkyQDJizszN Ml7KV2FPT0WU
LCLC-103H MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Ph[mlEPTB;Mj65NFQ{QCEQvF2= NEC0WlhUSU6JRWK=
SW1573 NGjkVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n6b2lEPTB;Mj65OlA5OiEQvF2= M4DhW3NCVkeHUh?=
MLMA MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXvT5lKSzVyPUKuPVY4OTdizszN MYrTRW5ITVJ?
NCI-H1355 M3vPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNwMEC3PVYh|ryP MVLTRW5ITVJ?
RMG-I M1P4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNwMEK1PVIh|ryP NELBPFJUSU6JRWK=
BB65-RCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HYS2lEPTB;Mz6wN|MyPCEQvF2= NFLaU3RUSU6JRWK=
PC-3 NX7zcodRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLyRnZKSzVyPUOuNFM5PzRizszN MX7TRW5ITVJ?
SF268 NIOyVnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3Je|l[UUN3ME2zMlA1PTJ|IN88US=> NYS2XpFjW0GQR1XS
NCI-H810 NHXPU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDRTWM2OD1|LkC0PFI{KM7:TR?= MknnV2FPT0WU
MEG-01 NHO1T|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInk[INKSzVyPUOuNFYyPjRizszN MV3TRW5ITVJ?
SW13 M3W1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLLTWM2OD1|LkC3PFQ4KM7:TR?= Ml7FV2FPT0WU
RH-1 NFrCWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPlTWM2OD1|LkGwNlc5KM7:TR?= NWLKb2lzW0GQR1XS
GT3TKB NYPseoViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTNwMUGyPFMh|ryP MXTTRW5ITVJ?
TK10 M1zWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXodHhJUUN3ME2zMlE{PzJ2IN88US=> MV;TRW5ITVJ?
T-24 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUToWYpkUUN3ME2zMlE2ODdizszN NYfmcI92W0GQR1XS
A498 M1n5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XsWmlEPTB;Mz6yNFg4OSEQvF2= MlG3V2FPT0WU
GR-ST Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfNT3pKSzVyPUOuNlIyOzlizszN NXfNV21rW0GQR1XS
LB2518-MEL M2HuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvpTWM2OD1|LkKyN|k5KM7:TR?= NF2wR5pUSU6JRWK=
T47D M3rIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTNwMkO2Nlch|ryP M4fpfHNCVkeHUh?=
NCI-H1651 NE\uWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjOZXRKSzVyPUOuNlQ3PDRizszN MV;TRW5ITVJ?
EC-GI-10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX2e|ZZUUN3ME2zMlI3OTV|IN88US=> NETpTZpUSU6JRWK=
HT-29 NUf6Rmd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H6fGlEPTB;Mz6yOlYyPCEQvF2= MXrTRW5ITVJ?
GI-ME-N MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHiTWM2OD1|LkK5OVEyKM7:TR?= NVvqNmY3W0GQR1XS
SW756 NXrGS5ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\xTWM2OD1|LkK5OlI6KM7:TR?= M1KxSHNCVkeHUh?=
RKO NYWyWI9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTNwM{C3OVch|ryP MXnTRW5ITVJ?
NCI-H1563 NIfrOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTNwM{OwNVgh|ryP MXLTRW5ITVJ?
DJM-1 NVPtfYJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHyVVkxUUN3ME2zMlM4Pjd2IN88US=> MnHmV2FPT0WU
L-428 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoroTWM2OD1|LkSwNFQ2KM7:TR?= NYDDXVUzW0GQR1XS
NCI-H2122 Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XtOWlEPTB;Mz60NVMyOiEQvF2= NGDKZpVUSU6JRWK=
Ca-Ski NGjwS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DPc2lEPTB;Mz60OVQ{KM7:TR?= MkHqV2FPT0WU
639-V NYnx[HlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjNTWM2OD1|LkS2NFU4KM7:TR?= NUXsVnJXW0GQR1XS
SW1116 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHvUW9[UUN3ME2zMlQ3OjZ7IN88US=> MXfTRW5ITVJ?
DMS-114 NEnFZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS0OWdIUUN3ME2zMlQ4ODZ4IN88US=> NGqzcWpUSU6JRWK=
MZ2-MEL M3TpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPMT4tQUUN3ME2zMlQ4PjhzIN88US=> M2PXbnNCVkeHUh?=
COLO-829 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLROWhKSzVyPUOuOVAxPzNizszN NHjIb29USU6JRWK=
J82 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XBUGlEPTB;Mz61NFU4KM7:TR?= NX65UXozW0GQR1XS
EW-13 NXTzZWJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoeyTWM2OD1|LkWyOVEh|ryP NX\STlc2W0GQR1XS
RXF393 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTNwNUOyPVQh|ryP NEX3V2dUSU6JRWK=
CAL-62 MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnGRmppUUN3ME2zMlU1PTF2IN88US=> MlnOV2FPT0WU
OCUB-M MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfkTWM2OD1|LkW0OlY2KM7:TR?= M1zjSXNCVkeHUh?=
BT-474 NUPa[lJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fa[2lEPTB;Mz62N|MyKM7:TR?= NY[xXXF6W0GQR1XS
KYSE-180 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XtWWlEPTB;Mz62N|M4OiEQvF2= NYjJUHVFW0GQR1XS
NCI-H650 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7md4txUUN3ME2zMlY1Ojh5IN88US=> NV3KNJdDW0GQR1XS
Detroit562 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;DTWM2OD1|Lk[1NFIzKM7:TR?= MV7TRW5ITVJ?
SW48 NGf6VYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNwNkW2OVch|ryP MVvTRW5ITVJ?
KYSE-450 NH:4Z2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTsd|hzUUN3ME2zMlY5PTh{IN88US=> MoToV2FPT0WU
KYSE-510 NU\RZo9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\KenlJUUN3ME2zMlczOThzIN88US=> NGDJZVBUSU6JRWK=
GP5d M4fxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfvTWM2OD1|LkeyPVUh|ryP MUPTRW5ITVJ?
RPMI-7951 NUfPdnM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn36TWM2OD1|Lke0O|I{KM7:TR?= NFnpPWpUSU6JRWK=
Becker NVv3[mVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNwN{WwNVIh|ryP MlHnV2FPT0WU
WM-115 M3SyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LuNmlEPTB;Mz63PFE6PSEQvF2= M4[0THNCVkeHUh?=
G-401 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTNwN{mwPFUh|ryP Ml3qV2FPT0WU
PANC-08-13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwN{m2NFIh|ryP NXPsZ3NMW0GQR1XS
SW982 NVWzWo1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLyTWM2OD1|LkiwOVUyKM7:TR?= NHj4O|dUSU6JRWK=
D-263MG NEXmZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNwOEKwOVEh|ryP MlznV2FPT0WU
KM-H2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwOEK2NlQh|ryP M1v3bnNCVkeHUh?=
SK-MEL-3 NUPZVlJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TMTGlEPTB;Mz64Nlg1OSEQvF2= M2XkbnNCVkeHUh?=
NCI-H1581 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LkdGlEPTB;Mz64OFQ5QCEQvF2= NELFSIZUSU6JRWK=
LS-123 NHHCeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNwOEe5NFkh|ryP NGrSNo9USU6JRWK=
CAKI-1 Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXwVmpKSzVyPUOuPFkxPTJizszN NHruWHdUSU6JRWK=
MEL-JUSO NVvrUm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HPT2lEPTB;Mz64PVE2OyEQvF2= NEnYT3BUSU6JRWK=
HCE-4 NGfzbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnrVZJxUUN3ME2zMlkyPjZ|IN88US=> M4nLeHNCVkeHUh?=
TE-10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEflN5BKSzVyPUOuPVIxOSEQvF2= MV;TRW5ITVJ?
OVCAR-4 NF32Z3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILqOZJKSzVyPUOuPVI5QDlizszN MVXTRW5ITVJ?
ETK-1 NVHYV4JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzX[ZlKSzVyPUOuPVQ3OzVizszN NHXWd|ZUSU6JRWK=
A2780 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnmco1KSzVyPUSuNFU6PjZizszN NX7xfW5mW0GQR1XS
LU-65 NGTPWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW4TWM2OD12LkC3OlM{KM7:TR?= M3nJfnNCVkeHUh?=
BHY M4q5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTBTWM2OD12LkGyOFk2KM7:TR?= MYTTRW5ITVJ?
COR-L105 NI\xZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnnPYI1UUN3ME20MlE{ODVzIN88US=> M3G4bXNCVkeHUh?=
CAL-12T M1j3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTRwMUOxNFMh|ryP NIfLVJRUSU6JRWK=
SCH M2\HSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDicFVoUUN3ME20MlE2PzR|IN88US=> NYf5WIx4W0GQR1XS
CW-2 M330d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknqTWM2OD12LkG5NFAyKM7:TR?= NYnjdnE2W0GQR1XS
HCC1806 NWrZdllyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PTWWlEPTB;ND6yNFMyOiEQvF2= Ml\2V2FPT0WU
KP-N-YN MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn0dohKSzVyPUSuNlA6OjdizszN MnjMV2FPT0WU
T98G NV72U4lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTRwMkKxOVch|ryP MUDTRW5ITVJ?
CAL-54 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTRwMkKzPFEh|ryP NFLid4FUSU6JRWK=
CAL-33 NGfoUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\UU2FKSzVyPUSuNlMxPjRizszN MojaV2FPT0WU
SNU-C2B NVHIT3RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\rfGlEPTB;ND6yOFc3QSEQvF2= M3\D[HNCVkeHUh?=
NUGC-3 NIDyUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK0cZpDUUN3ME20MlI2PTB3IN88US=> NGPNd|ZUSU6JRWK=
DOK MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXOSllKSzVyPUSuNlY2QTNizszN MnjVV2FPT0WU
MMAC-SF NX3ZZXNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTRwMk[4OVkh|ryP NGSxXZJUSU6JRWK=
KYSE-70 M4jTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTRwMkmzOEDPxE1? MX;TRW5ITVJ?
A204 NF\HO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPpfXNDUUN3ME20MlM2QDB|IN88US=> MXfTRW5ITVJ?
SCC-25 NUHyPIZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTRwM{W4NVkh|ryP M{[zZXNCVkeHUh?=
EPLC-272H MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXXcGVKSzVyPUSuN|g6PSEQvF2= NUmwdmFLW0GQR1XS
CAL-120 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TOUmlEPTB;ND6zPFk6OiEQvF2= M2iwNnNCVkeHUh?=
LS-513 M2niWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[xVmlEPTB;ND60NlE6QCEQvF2= NIrYRnlUSU6JRWK=
CAPAN-1 M2XIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTTTWM2OD12LkSyN|gzKM7:TR?= NYLUWJd{W0GQR1XS
ESS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjzZVRKSzVyPUSuOFI4OjRizszN NV3XeWZrW0GQR1XS
GMS-10 MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jldGlEPTB;ND60NlgyQSEQvF2= MknyV2FPT0WU
NCI-N87 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCwVGRPUUN3ME20MlUxQDZ6IN88US=> MmPEV2FPT0WU
HMV-II MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HBNWlEPTB;ND61NVc{KM7:TR?= NFHvWWhUSU6JRWK=
COLO-741 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTRwNUW5PVQh|ryP M3vsPHNCVkeHUh?=
MKN45 M2DKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rxc2lEPTB;ND61O|c{OiEQvF2= NGP5W|hUSU6JRWK=
OAW-28 M4\kR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jvfGlEPTB;ND61PFM6QCEQvF2= NV3lTm9JW0GQR1XS
OCI-AML2 NFjXfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;RcZpZUUN3ME20MlY2OjN6IN88US=> NUOw[41MW0GQR1XS
MDA-MB-231 M2fnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTRwN{CyOFMh|ryP NHr5bWRUSU6JRWK=
NCI-H1648 NULCdIFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfjbIRKSzVyPUSuO|IzPzNizszN M1u0cHNCVkeHUh?=
NCI-H1792 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPyTWM2OD12Lke2NVA4KM7:TR?= NUD0cZhpW0GQR1XS
GCIY M4DFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHvTWM2OD12Lke3OFI1KM7:TR?= MXPTRW5ITVJ?
Hs-578-T MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7NTXRKSzVyPUSuO|c3PTVizszN NUPwVopIW0GQR1XS
SW962 NWT6cmhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTRwN{iwNVEh|ryP NX;pPFdZW0GQR1XS
NCI-H630 M1XnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TB[2lEPTB;ND63PFA5OSEQvF2= NVTqeXVWW0GQR1XS
786-0 NGrNcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXYc4dCUUN3ME20Mlc5Pzd|IN88US=> NWTCVohYW0GQR1XS
FTC-133 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTRwN{myOlMh|ryP NGXrcXpUSU6JRWK=
BT-20 NXXCWndwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L1VWlEPTB;ND63PVQzQSEQvF2= NWTLV3puW0GQR1XS
Mewo MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmyTWM2OD12LkixO|Q4KM7:TR?= MoXUV2FPT0WU
SW780 M1;BOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M12xXWlEPTB;ND64OVc3PiEQvF2= MU\TRW5ITVJ?
OE33 M1PId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTRwOEe3NVMh|ryP MmLSV2FPT0WU
HCC1569 M2izeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HsOGlEPTB;ND64PFQ2QCEQvF2= MnLoV2FPT0WU
TE-6 M2LVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTRwOUO5O|ch|ryP NHLZUHdUSU6JRWK=
SK-N-FI Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjhTWM2OD12Lkm0OFIyKM7:TR?= M1TWfnNCVkeHUh?=
PANC-03-27 M2Djdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwOUm5OlIh|ryP Mk\vV2FPT0WU
MCF7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPHTWM2OD13LkCwO|M5KM7:TR?= M{W4cXNCVkeHUh?=
UACC-257 NITrTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\TVVBKSzVyPUWuNFI5PDVizszN MXvTRW5ITVJ?
SW1088 M3jMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XISGlEPTB;NT6wNlk1PCEQvF2= NUnVbplLW0GQR1XS
A704 NVXFfm92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHkcGhKSzVyPUWuNFMxPiEQvF2= MlLPV2FPT0WU
A2058 NHrHenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTVwMEW5NFgh|ryP M{PNWnNCVkeHUh?=
Calu-3 M3e0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrnfpJKSzVyPUWuNFY1PTJizszN M4ew[nNCVkeHUh?=
RERF-LC-MS MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfn[I1nUUN3ME21MlA3QTB|IN88US=> NWnCVZU1W0GQR1XS
AU565 NXGxTIZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\SWFlKSzVyPUWuNFk4ODJizszN MUjTRW5ITVJ?
DMS-79 M4[3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDOTWM2OD13LkGzPFg{KM7:TR?= MlPvV2FPT0WU
DK-MG NWPjZZIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC0TWM2OD13LkG4OFM5KM7:TR?= MofwV2FPT0WU
HuCCT1 NY[zSVhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPl[203UUN3ME21MlI{QDV4IN88US=> MUHTRW5ITVJ?
HT-144 NGfYW|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrBZnA6UUN3ME21MlI1QTh5IN88US=> NYfqZXFYW0GQR1XS
M059J NFKw[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHkeYNKSzVyPUWuNlU4PiEQvF2= MoDTV2FPT0WU
COLO-792 M1f4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTiT5BwUUN3ME21MlI3OzV4IN88US=> NXjUR5FpW0GQR1XS
SF539 NHq4eoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TLWGlEPTB;NT6yOlY{OiEQvF2= MoDNV2FPT0WU
SK-UT-1 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyxTWM2OD13LkK3O|UyKM7:TR?= NYfwO3RbW0GQR1XS
NCI-H1703 Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PB[mlEPTB;NT6zOVgzPiEQvF2= NILPWHpUSU6JRWK=
SW837 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\oTWM2OD13LkO3PFc5KM7:TR?= Mn62V2FPT0WU
U251 NEntZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17Vd2lEPTB;NT6zPVA6PiEQvF2= MnTlV2FPT0WU
SW1710 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TSUWlEPTB;NT60NVU2PCEQvF2= NYfaXolRW0GQR1XS
NCI-H1299 NIraWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTVwNE[zN|Uh|ryP M{fLUXNCVkeHUh?=
RVH-421 MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXK5eGFQUUN3ME21MlQ6QTB6IN88US=> MlLFV2FPT0WU
UM-UC-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDpdlFKSzVyPUWuOlI3PTFizszN Mkn4V2FPT0WU
MDA-MB-175-VII MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESzT5pKSzVyPUWuOlQxPDFizszN MmL0V2FPT0WU
KYSE-270 NInvZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHEcm5HUUN3ME21MlY3ODNzIN88US=> MXjTRW5ITVJ?
COLO-668 M3nr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvDTnd2UUN3ME21MlcyOzJizszN NEe2bolUSU6JRWK=
LN-405 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTVwN{OwPFUh|ryP NIHTRmtUSU6JRWK=
HT-1376 NFnIcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDRZ4hKSzVyPUWuO|gxPTJizszN NYP5NohpW0GQR1XS
769-P M4rkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfaTWM2OD13Lki2O|E5KM7:TR?= NWnnbXdoW0GQR1XS
HuP-T3 NVvlUGRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n2[mlEPTB;NT64PFY4PyEQvF2= M3HiSXNCVkeHUh?=
MDA-MB-415 NUC1WGtYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7ReIdKSzVyPUWuPVIyOzlizszN MmrkV2FPT0WU
MKN7 MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDzTWM2OD13Lkm4PEDPxE1? MX3TRW5ITVJ?
KS-1 M2K0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj2VFJXUUN3ME21Mlk5QDN4IN88US=> NG\QS41USU6JRWK=
647-V NE\4U4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTVwOUmxOFgh|ryP NInSWpdUSU6JRWK=
COLO-679 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nUe2lEPTB;Nj6wNFI2PSEQvF2= M3npcnNCVkeHUh?=
AN3-CA M1LlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTZwMEO0OFEh|ryP MmDHV2FPT0WU
C32 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLBfFh{UUN3ME22MlE{ODN2IN88US=> NXuxW3d5W0GQR1XS
KM12 M{\reGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTZwMkSwPVkh|ryP NWTNWGIzW0GQR1XS
KINGS-1 NFn4UmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTZwMk[xOVIh|ryP MXrTRW5ITVJ?
KYSE-410 NVH1[VJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTZwM{C2OFUh|ryP MkDOV2FPT0WU
HPAF-II M2GyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2j4XmlEPTB;Nj6zOVQ5KM7:TR?= NITET4ZUSU6JRWK=
LAN-6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS3fFl2UUN3ME22MlQ6PjNzIN88US=> MlXyV2FPT0WU
LU-99A NXXoUJdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7MW5ZLUUN3ME22MlU2QTh7IN88US=> Mn\PV2FPT0WU
SJSA-1 NUfzXHBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGzd2JEUUN3ME22MlU3OzR5IN88US=> MkCxV2FPT0WU
MSTO-211H MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTZwN{KyN|Mh|ryP Mk\sV2FPT0WU
SW900 M4rVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTZwN{[yNlEh|ryP NEXhbGJUSU6JRWK=
LNCaP-Clone-FGC Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv1TWM2OD14LkiwOFA{KM7:TR?= M2\IfHNCVkeHUh?=
OMC-1 NX3TNXR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnxTWM2OD14Lki1OFAzKM7:TR?= M2LCTnNCVkeHUh?=
IST-MEL1 M4Lkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTZwOEm2Olkh|ryP NI\GPWVUSU6JRWK=
TE-9 NIjJSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzDXmFKSzVyPU[uPFk5PDdizszN M3zQdHNCVkeHUh?=
NCI-H2030 NIfrbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rZVmlEPTB;Nj65NVIzPiEQvF2= MUPTRW5ITVJ?
BFTC-909 M3XPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrsXI9DUUN3ME23MlAxPjRzIN88US=> NV[xWYRFW0GQR1XS
NCI-SNU-5 NGnVO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjvTWM2OD15LkCyNVU6KM7:TR?= NVnvSFFVW0GQR1XS
TE-5 M2fQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zRWmlEPTB;Nz6wNlg5OSEQvF2= M3TQXHNCVkeHUh?=
SK-MES-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTdwMEW0Nlch|ryP M1nNSXNCVkeHUh?=
SHP-77 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTdwMUO5OVIh|ryP M4PabnNCVkeHUh?=
NCI-H1623 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfYWW5zUUN3ME23MlE1ODd{IN88US=> MYHTRW5ITVJ?
TE-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvtbmJKSzVyPUeuNVUyQDRizszN NE\HfolUSU6JRWK=
EKVX NWW3U2d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTdwMUmyOlch|ryP MYfTRW5ITVJ?
OVCAR-3 NETKdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTdwMkGxN|Mh|ryP MYPTRW5ITVJ?
C3A Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP4TWM2OD15LkO0OVIh|ryP MkTRV2FPT0WU
CFPAC-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\zWHV7UUN3ME23MlM3OjJ{IN88US=> MV;TRW5ITVJ?
MG-63 MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTdwNEG4OFkh|ryP NWTsNXRFW0GQR1XS
KYSE-140 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HEO2lEPTB;Nz60OFA3OSEQvF2= NFvSSGVUSU6JRWK=
MPP-89 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33GPGlEPTB;Nz61PVczQSEQvF2= MkT1V2FPT0WU
COLO-824 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjZPZp4UUN3ME23MlczQDZ|IN88US=> M1rL[XNCVkeHUh?=
SiHa NILF[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HzbmlEPTB;Nz64N|cxPyEQvF2= MmrmV2FPT0WU
SNU-387 NXrJWlhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPPOnE2UUN3ME23Mlg2OzR5IN88US=> MUDTRW5ITVJ?
A172 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfhXoJlUUN3ME23Mlg3OTd{IN88US=> NFrUfIhUSU6JRWK=
COLO-680N M37JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;IeW92UUN3ME23MlkyPzNizszN NFfOVnBUSU6JRWK=
HCC1395 NGmybW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnSTWM2OD16LkC1OFUzKM7:TR?= MX3TRW5ITVJ?
NCI-H28 M4e0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfJVYs1UUN3ME24MlA2QTZ|IN88US=> NXjVOGF1W0GQR1XS
LC-2-ad NXnjR3hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELrOlFKSzVyPUiuNlE6OzdizszN NFHzfZpUSU6JRWK=
S-117 NH\aOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRThwMkWzOVMh|ryP M3X4Z3NCVkeHUh?=
NCI-H1838 Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmwWFlKSzVyPUiuNlU4QDFizszN MnTkV2FPT0WU
PANC-10-05 NYLVXlZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLqTHBKSzVyPUiuN|cxPDdizszN NVHGOnc1W0GQR1XS
KALS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLlTWM2OD16LkWwPVI5KM7:TR?= M2\zcXNCVkeHUh?=
LS-1034 M3\6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;kVGhLUUN3ME24MlU4PDN5IN88US=> MXrTRW5ITVJ?
TGBC1TKB NFT4NWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\CN5d{UUN3ME24Mlc{PTN3IN88US=> NXTjOXJ2W0GQR1XS
OE19 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\0WI9KSzVyPUiuO|YzPjJizszN NUG1VGVUW0GQR1XS
D-502MG NGnGfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRThwN{[5PVQh|ryP M4TudnNCVkeHUh?=
JEG-3 NW\LbJhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DzfWlEPTB;OD63PFYyQCEQvF2= MmWyV2FPT0WU
DBTRG-05MG MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jjfWlEPTB;OD64O|U3PSEQvF2= MUXTRW5ITVJ?
ME-180 Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjre3dKSzVyPUmuNFY4OjVizszN NUnQb|FiW0GQR1XS
NCI-H1573 NX3WeIt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS0fWpKSzVyPUmuNVA2OzJizszN M{XjWHNCVkeHUh?=
HCC2998 M{DXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v1TWlEPTB;OT6xN|Y5OSEQvF2= M3X2fnNCVkeHUh?=
ACHN MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHjVWJQUUN3ME25MlI1QTd3IN88US=> NEfpOmNUSU6JRWK=
D-392MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorFTWM2OD17LkK1O|E2KM7:TR?= NFnldlVUSU6JRWK=
no-11 NWTTdodVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInFNXBKSzVyPUmuNlYxOjhizszN MWLTRW5ITVJ?
KLE NFTWfFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fZPGlEPTB;OT6zNlI{OiEQvF2= MX;TRW5ITVJ?
Calu-6 NFS4O41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPB[FRKSzVyPUmuN|c2OjhizszN NGDaSFVUSU6JRWK=
LB831-BLC NVTCdZM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3UT3VKSzVyPUmuOFUyPzFizszN M1TQUnNCVkeHUh?=
SW684 NHKwU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP4ZotKSzVyPUmuOFYyOTZizszN M3;TVnNCVkeHUh?=
SH-4 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ThSmlEPTB;OT60PVM3PCEQvF2= MVHTRW5ITVJ?
IST-MES1 M3nvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW1OG5KSzVyPUmuOVE3PDRizszN Moe2V2FPT0WU
Saos-2 NEHN[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3RTWM2OD17LkWyNVk2KM7:TR?= MoXLV2FPT0WU
NCI-H2087 NFjjU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonHTWM2OD17Lk[3N|UzKM7:TR?= MUXTRW5ITVJ?
SCC-9 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPN[YVKSzVyPUmuO|E5OTZizszN NVz3bYVtW0GQR1XS
MFE-280 NVTSRmdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTlwN{K3PFUh|ryP NGjSeHlUSU6JRWK=
BEN MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXkXYVKSzVyPUmuPFIyPTlizszN NVzuW45KW0GQR1XS
CP50-MEL-B NXXr[IZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTlwOUK0N|Ih|ryP NX[4c2dIW0GQR1XS
SK-MEL-28 MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\zTWM2OD1zMD6wNVk{KM7:TR?= MlvpV2FPT0WU
NCI-H2452 NU\FXWQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTVUmMzUUN3ME2xNE4yPiEQvF2= MlLoV2FPT0WU
NCI-H1395 M2nVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TXSWlEPTB;MUCuNVc5KM7:TR?= MXjTRW5ITVJ?
NCI-H2052 NWriWGU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm3[HBKSzVyPUGwMlE5QDJizszN M2rUNnNCVkeHUh?=
A375 NGL1cVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\ISWlEPTB;MUCuNlQ2OiEQvF2= MUjTRW5ITVJ?
HCC38 M3nTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfoTWM2OD1zMD6zNlIh|ryP MXLTRW5ITVJ?
LK-2 Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rob2lEPTB;MUCuOFIxQCEQvF2= NITUbXNUSU6JRWK=
SF126 NXPIZXBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zkPGlEPTB;MUCuOFczPyEQvF2= MX;TRW5ITVJ?
SK-MEL-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;OR2F5UUN3ME2xNE44QDN6IN88US=> MmrMV2FPT0WU
ACN M4C0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFyLki2O|kh|ryP NGP4bJNUSU6JRWK=
BB30-HNC M1rkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHuTWM2OD1zMD64O|EyKM7:TR?= MoLGV2FPT0WU
NCI-H747 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm0TWM2OD1zMD64O|Q3KM7:TR?= NXe2ZnNXW0GQR1XS
KYSE-150 M{\GcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFzLkCzPFch|ryP M1X1fXNCVkeHUh?=
D-247MG NGDEPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzHTWM2OD1zMT6xNFA6KM7:TR?= MkGwV2FPT0WU
BxPC-3 M4HFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFzLkO3OFch|ryP NE\FTllUSU6JRWK=
SK-MEL-30 NEDET3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFzLkSwO|kh|ryP Mmn2V2FPT0WU
CAS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\Z[WxKSzVyPUGxMlQyODlizszN NYTkZ2NVW0GQR1XS
no-10 NEHDTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z0UWlEPTB;MUKuNVIyPyEQvF2= MXnTRW5ITVJ?
NCI-H2405 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HpeWlEPTB;MUKuNlA{PiEQvF2= MofUV2FPT0WU
KGN NH7JcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nIOGlEPTB;MUKuNlkxOSEQvF2= NWrpbpJ4W0GQR1XS
BB49-HNC M{TCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW1TWM2OD1zMj6zPVU3KM7:TR?= M4XUeHNCVkeHUh?=
NCI-H1693 Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrjPVJKSzVyPUGyMlU5OTZizszN MUTTRW5ITVJ?
RO82-W-1 NH\VXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DXZmlEPTB;MUOuNFY1QSEQvF2= NVLSSJNCW0GQR1XS
CAL-85-1 M4PYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XiUmlEPTB;MUOuOFM6QSEQvF2= M4TMZnNCVkeHUh?=
H-EMC-SS MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF|LkmxNFQh|ryP M4PTNnNCVkeHUh?=
SW1783 MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;4TWM2OD1zND6yN|kyKM7:TR?= NYPJSZhkW0GQR1XS
LB771-HNC M2HE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;kXmlEPTB;MUSuOFE6KM7:TR?= M1i3cnNCVkeHUh?=
HCC70 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm0TWM2OD1zND60NlM{KM7:TR?= Mk[xV2FPT0WU
KNS-81-FD NELhVnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLMTWM2OD1zND63NFQ2KM7:TR?= NYrTbFIxW0GQR1XS
KYSE-520 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\OSGlEPTB;MUSuPVI4KM7:TR?= NXHvS403W0GQR1XS
TGBC24TKB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuxS2R5UUN3ME2xOE46PTN7IN88US=> MXHTRW5ITVJ?
SNB75 NXP5Onp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Lm[WlEPTB;MUWuNFczQSEQvF2= Mke2V2FPT0WU
SW872 NUTEXWZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzVUJBNUUN3ME2xOU4zOjF6IN88US=> MV;TRW5ITVJ?
U031 Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlOzTWM2OD1zNT64NFI5KM7:TR?= NFLqcFFUSU6JRWK=
ChaGo-K-1 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3HVJJKSzVyPUG1Mlg{PTlizszN Ml;EV2FPT0WU
NCI-H441 NVu3cY92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jt[2lEPTB;MU[uNFA{QSEQvF2= NXP4eHRQW0GQR1XS
TE-12 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHoe2FZUUN3ME2xOk4yQDd|IN88US=> MUjTRW5ITVJ?
NCI-H1755 M33teGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi1U3dKSzVyPUG2MlU4OyEQvF2= MY\TRW5ITVJ?
KNS-42 NWm4WI44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjEeoU6UUN3ME2xOk43PTh7IN88US=> NUOyWFIyW0GQR1XS
SK-PN-DW MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHKTWM2OD1zNz60NlAyKM7:TR?= NXXCU5JlW0GQR1XS
NCI-H226 MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;aTWM2OD1zNz65N|Q2KM7:TR?= NGiyUXVUSU6JRWK=
K-562 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LqXmlEPTB;MUiuOlMyPyEQvF2= NILrbndUSU6JRWK=
A388 M2DhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uzSGlEPTB;MUmuNFMxOyEQvF2= MlrrV2FPT0WU
ZR-75-30 Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LMZ2lEPTB;MUmuNFk3QCEQvF2= NH\WOmNUSU6JRWK=
LU-135 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v4SWlEPTB;MUmuNlY{PiEQvF2= MUDTRW5ITVJ?
NCI-H2029 NWXEU5hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;pRVZXUUN3ME2xPU43ODJzIN88US=> NHrWeJRUSU6JRWK=
HT-1197 M3WwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\0TWM2OD1zOT65NlI4KM7:TR?= MnHMV2FPT0WU
IGR-1 NVO0fVdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\3fZlKSzVyPUKwMlMyOTdizszN NWOzR3hNW0GQR1XS
U-87-MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH5TWM2OD1{MD62OFE{KM7:TR?= MmLQV2FPT0WU
NCI-H1304 NE\vd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr0TWM2OD1{MD63OVAyKM7:TR?= MmnXV2FPT0WU
RCC10RGB NHrPbmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfsR5I5UUN3ME2yNU4zQDJ7IN88US=> MWPTRW5ITVJ?
NCI-H520 M332RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\NTWM2OD1{Mj63OlEyKM7:TR?= MkDSV2FPT0WU
SK-LU-1 MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;jTWM2OD1{Mz6wO|E5KM7:TR?= NVPjeG83W0GQR1XS
UACC-893 NU\SNHNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjSOJRpUUN3ME2yN{4yODN6IN88US=> M3LTOHNCVkeHUh?=
NCI-H2347 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDZbZFKSzVyPUKzMlI3PzRizszN M{jYdnNCVkeHUh?=
U-118-MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDnTWM2OD1{Mz63NlE4KM7:TR?= NX\TOXdTW0GQR1XS
NCI-H596 NXnGdWlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrhTWM2OD1{Mz65NFU2KM7:TR?= NXLRSJhwW0GQR1XS
MZ1-PC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ZN21KSzVyPUK0MlY4PTlizszN MXPTRW5ITVJ?
SW1417 MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KxV2lEPTB;MkWuNlQ6QCEQvF2= NXTHcHJXW0GQR1XS
NCI-H82 NXnJUHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PLO2lEPTB;Mk[uOFI5QCEQvF2= M3y1XnNCVkeHUh?=
COLO-678 NHHLb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO2d|dKSzVyPUK3MlQ6OTlizszN MYLTRW5ITVJ?
KURAMOCHI M1Ly[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnixTWM2OD1{OD6xNlYh|ryP MXvTRW5ITVJ?
NCI-H1650 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjocYtKSzVyPUOwMlE6OjRizszN M4TlenNCVkeHUh?=
HCC1954 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXNXVhKSzVyPUOxMlM3PjZizszN NX:xeVVnW0GQR1XS
GAK MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW4VlN[UUN3ME2zNk4zPjF4IN88US=> NXjrNoFRW0GQR1XS
YAPC M1vz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS2T2hKSzVyPUOzMlc3PDhizszN NEXpPXpUSU6JRWK=
NCI-H2228 M2\scGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTN2LkO2NFUh|ryP NY\PfoVTW0GQR1XS
VMRC-RCZ MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDsTWM2OD1|Nj6zNFIzKM7:TR?= MUDTRW5ITVJ?
NMC-G1 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXZVJVQUUN3ME2zO{4xPTJ7IN88US=> M4HQdHNCVkeHUh?=
D-336MG NWPlUFVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTRzLki0OFIh|ryP MWXTRW5ITVJ?
UACC-62 M4H5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL1UZltUUN3ME20Nk42PTB3IN88US=> MXLTRW5ITVJ?
C-33-A NIXMOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TvVWlEPTB;NEWuN|I2PiEQvF2= Mn7SV2FPT0WU
HCC1937 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;DTWM2OD12Nz6xPVU5KM7:TR?= MmruV2FPT0WU
HDLM-2 NVfGOHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTR5LkKyPFch|ryP Mor5V2FPT0WU
NCI-H727 NGH0c3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DRTWlEPTB;NEeuNlQ2OSEQvF2= MXHTRW5ITVJ?
NY M3PL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTR7LkO5NFgh|ryP MX7TRW5ITVJ?
NCI-H2291 M2jJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHQTWM2OD12OT64N|AyKM7:TR?= M4jKV3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Ac-Histone H4/Ac-Histone H3; 

PubMed: 21598070     


D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. 

phospho-CDK1; 

PubMed: 21598070     


Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. 

phospho-Cdc25c/Cdc25c; 

PubMed: 21598070     


Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM).

Cyclin B1; 

PubMed: 21598070     


Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h.

c-Myc/c-Raf/Akt/Cyclin D1/CDK4; 

PubMed: 19440035     


Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat  were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control.

p-eIF2α/ATF4/CHOP ; 

PubMed: 20072656     


Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure.

p21; 

PubMed: 21598070     


To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.

21598070 19440035 20072656
Immunofluorescence
HDAC1/CK19; 

PubMed: 29917299     


Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment.

Nrf2; 

PubMed: 20566897     


Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat.

α-SMA; 

PubMed: 26330748     


Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm.

Ac-STAT3/IGF2; 

PubMed: 27086926     


Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.

29917299 20566897 26330748 27086926
Growth inhibition assay
Cell apoptosis; 

PubMed: 19440035     


Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE)

Cell viability; 

PubMed: 27086926     


The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).

19440035 27086926
ELISA
IGF2; 

PubMed: 27086926     


Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. 

IL-13/IL-10/IL-5; 

PubMed: 18541724     


Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM).

M-CSF; 

PubMed: 23042302     


Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF  secretion. *P < 0.05 and **P < 0.001 versus control treatment. 

MMP-9; 

PubMed: 23042302     


Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. *P < 0.05 and **P < 0.001 versus control treatment. 

27086926 18541724 23042302
In vivo Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. [2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoprecipitation-HDAC assays:

The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an 3H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [3H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research:

[2]

+ Expand
  • Cell lines: LNCaP, PC-3, and TSU-Pr1
  • Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM
  • Incubation Time: 1, 2, 3 and 4 days
  • Method:

    Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells
  • Formulation: Dissolved in DMSO
  • Dosages: ~100 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 52 mg/mL (196.74 mM)
Ethanol 3 mg/mL (11.35 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 264.3
Formula

C14H20N2O3

CAS No. 149647-78-9
Storage powder
in solvent
Synonyms SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03022565 Recruiting Uveal Melanoma University of Miami|University of Miami Sylvester Comprehensive Cancer Center July 2019 Early Phase 1
NCT03022565 Recruiting Uveal Melanoma University of Miami|University of Miami Sylvester Comprehensive Cancer Center July 2019 Early Phase 1
NCT03843528 Not yet recruiting Acute Myeloid Leukemia|Myelodysplastic Syndromes|Mixed Phenotype Acute Leukemia|Juvenile Myelomonocytic Leukemia Johns Hopkins All Children''s Hospital May 1 2019 Phase 1
NCT03843528 Not yet recruiting Acute Myeloid Leukemia|Myelodysplastic Syndromes|Mixed Phenotype Acute Leukemia|Juvenile Myelomonocytic Leukemia Johns Hopkins All Children''s Hospital May 1 2019 Phase 1
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System April 1 2019 Phase 1
NCT03742245 Not yet recruiting Breast Cancer Metastatic|Breast Cancer Jenny C. Chang MD|AstraZeneca|The Methodist Hospital System April 1 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommendation about reconstitution of the compound for in vivo animal study?

  • Answer:

    We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) supplier | purchase Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) cost | Vorinostat (SAHA, MK0683) manufacturer | order Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID